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"Science is always wrong. It never 
solves a problem without creating ten 
more" (George Bernard Shaw) 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
 
An important feature of oral squamous cell carcinomas (OSCC) is the acquisition 
of α-smooth muscle actin (α-SMA)-positive fibroblasts, termed myofibroblasts or 
cancer-associated fibroblasts (CAF), into the adjacent stroma. The aims of this study 
were: 1) to assess through meta-analysis the potential of CAF as prognostic marker 
for OSCC, 2) to determine the role of extracellular vesicles (EV) released by CAF in 
invasion of OSCC cells, and 3) to evaluate the prognostic relevance of ROCK2 tumor 
expression, which is secreted by CAF, in patients with OSCC. In the meta-analysis, 
pooling data from 12 eligible studies comprising 1328 patients revealed that high 
presence of CAF in the stroma of OSCC significantly predicted shortened time to 
relapse (HR= 3.32, 95% CI: 2.09-5.26, p<0.00001) and an overall decrease in survival 
(HR: 2.16, 95% CI: 1.60-2.92, p<0.00001). In comparison with EV isolated from normal 
oral fibroblasts (NOF), CAF-EV promoted a disseminated pattern of invasion 
associated with significant increase in migration and invasion of the OSCC cells. 
Interactome network analysis of NOF- and CAF-EV and OSCC-treated cells with EV 
showed enrichment for metabolic and focal adhesion pathways. Regarding ROCK2 
expression, our results showed that advanced clinical stage (p=0.002) and increased 
density of CAF (p=0.002) are significantly associated with high ROCK2 expression, 
and high expression of ROCK2 is related to shortened disease-specific survival (HR: 
2.22, 95% CI: 1.15-4.38, p=0.04). Our results show that the presence of CAF is a 
marker of poor OSCC prognosis, and CAF are relevant in supporting OSCC cell 
invasion. High expression of ROCK2 in OSCC is associated with advanced disease 
and follows the increase in CAF density, suggesting the organization of a more 
invasion-permissive microenvironment, facilitating tumor progression.  
 
 
Keywords: Oral squamous cell carcinoma; cancer-associated fibroblast; prognosis; 
extracellular vesicles; ROCK2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESUMO 
 
Uma importante característica dos carcinomas epidermóides orais (CEO) é a 
aquisição de fibroblastos que expressam a isoforma alfa da actina de músculo liso (α-
SMA) no estroma adjacente, denominados miofibroblastos ou fibroblastos associados 
ao câncer (CAF, do inglês cancer-associated fibroblasts). Os objetivos deste estudo 
foram: 1) avaliar por meio de uma metanálise o potencial de CAF como marcador 
prognóstico para os CEO, 2) determinar o papel das vesículas extracelulares (VE) 
secretadas por CAF na indução da invasão celular em CEO, 3) avaliar o valor 
prognóstico da expressão tumoral de ROCK2, que é também secretada por CAF, em 
pacientes com CEO. A metanálise selecionou 12 estudos elegíveis, abrangendo um 
total de 1328 pacientes, e revelou que a elevada presença de CAF no estroma dos 
CEO pode significativamente predizer uma diminuição no tempo para a recidiva (HR: 
3,32, 95% CI: 2,09-5,26, p<0,00001) e diminuição na sobrevida global do paciente 
(HR: 2,16, 95% CI: 1,60-2,92, p<0,00001). Em comparação com VE derivadas de 
fibroblastos orais normais (FON), CAF-VE promoveram um padrão disseminado de 
invasão tumoral,o qual é associado com um aumento significativo na migração e 
invasão das células tumorais.As análises interactômicas de FON- e CAF-VE e de 
células de CEO tratadas com VE demonstraram um enriquecimento para diferentes 
vias metabólicas e de adesão focal. No tocante à expressão de ROCK2, nossos 
resultados mostraram que o estadiamento clínico avançado (p=0,002) e o aumento na 
densidade de CAF (p=0,002) estão significativamente associados com o aumento na 
expressão tumoral de ROCK2 e alta expressão de ROCK2 está relacionada à 
diminuição da sobrevida específica (HR: 2,22, 95% CI: 1,15-4,38, p=0,04). Os 
resultados deste estudo mostram que a presença de CAF é um indicador de pior 
prognóstico para CEO, e CAF são relevantes no suporte da invasão das células de 
CEO. Elevada expressão de ROCK2 em CEO está associada com doença avançada 
e acompanha o aumento da densidade de CAF, sugerindo a organização de um 
microambiente permissivo à invasão, facilitando a progressão tumoral. 
 
 
Palavras-chave: carcinoma epidermóide oral; fibroblastos associados ao câncer; 
prognóstico; vesículas extracelulares; ROCK2. 
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1 INTRODUCTION 
 
Oral squamous cell carcinoma (OSCC) is one of the most common cancers 
in the world and is the major subtype of the head and neck, displaying many 
pathological differences to other cancers in this region (Malik et al., 2016). In 2012, 
529.500 patients were diagnosed with a lip, oral cavity or pharyngeal cancer (70.8% 
or 375.000 men and 29.2% or 154.500 women), a scenario that is predicted to increase 
by 62% to 856.000 cases by 2035 because of changes in demographics (Shield et al., 
2017). Among these, OSCC presented the highest frequency, with an incidence of 
approximately 202.000 cases (Shield et al., 2017). While these rates vary widely 
among different populations (there is approximately 20-fold geographical variation), 
two-thirds of these cases occur in developing countries (Warnakulasuryia, 2009). The 
incidence of OSCC has decreased in some countries, but a high incidence is still found 
in South Asian countries, including India, Pakistan, and Sri Lanka, where oral cancer 
is the most common cancer in men and may represent up to 25% of all new cases of 
cancer (Müller, 2017). Overall in the European Union, oral and pharyngeal are the 7th 
most common types of cancer. In recent decades, several Central and Eastern 
European countries such as Hungary, Slovakia, and Slovenia, have reported high rates 
of oral cancer. Together with Greece and Sweden, Finland has the lowest incidence 
rates of OSCC within Europe. In South America and the Caribbean, cancers of mouth 
and pharynx rank fifth in men and sixth in women. The region comprising Argentina, 
Southern Brazil and Uruguay have the highest incidence, though high rates are 
observed in all regions of Brazil (Warnakulasuryia, 2009). 
The major risk factors for OSCC remain smoking with a synergistic 
association with alcohol consumption, typically occurring in the elderly during the fifth 
through the eighth decades of life (Bodner et al., 2014; Müller et al., 2017). Patients 
younger than 40 years old account for less than 4% of all oral malignancies (Bodner 
et al., 2014). There is currently an increase in patients with OSCC without classical risk 
factors and these patients are often young adults (18–44 years) and female (Kansy et 
al., 2012). Although human papillomavirus (HPV), particularly type 16, is mentioned as 
an etiologic factor in the development of OSCC, it is generally acknowledged that HPV-
driven OSCC accounts for a very small percentage (1–10%) of cancers (Müller, 2017). 
For that reason, the oropharynx tumors were separated in a standalone chapter of the 
15 
 
4th Edition of the World Health Organization Classification of Head and Neck Tumours, 
due to the differences of the oropharynx from the oral cavity (WHO, 2017). Whereas 
HPV-related oropharyngeal cancers are more likely to occur in men who are non-
smokers, non-drinkers and have a good socioeconomic status, oral (freely mobile 
portion) tongue cancer mostly affects young white women with unknown causes at the 
moment (Hussein et al., 2017). 
Due to a high potential for local invasion and lymph node metastasis, the 
overall 5-year survival rate of OSCC patients is around 50-60% and has not improved 
significantly during the past decades (Chin et al. 2015). Although more than 80% of 
early-stage OSCCs can be cured, ~70% of patients with the progressive disease 
cannot be cured (Sasahira et al., 2014). The limited survival rates for patients with oral 
cancer are likely to be the result of a high proportion of patients presenting at an 
advanced stage of disease that may not respond to available therapies (Al-Swiahb et 
al., 2010). To choose the initial treatment for OSCC, there are several factors related 
to the primary tumor and patient characteristics. The tumor factors include primary site, 
size, location, proximity to the bone, the status of cervical lymph nodes, previous 
treatment and histological characteristics, such as the type, grade, and depth of 
invasion of the tumor (Noguti et al., 2012). The depth of invasion or tumor thickness is 
a dimension of tumor size that likely reflects the proximity to an underlying lymph-
vascular structure, and was recently incorporated in the T stage classification from the 
8th edition of the staging manual of the American Joint Cancer Committee (Ridge et 
al, 2017). The patient characteristics that influence the treatment of choice are related 
to age, general medical condition, tolerance to treatment and lifestyle. There are 
various approaches to treatment of OSCC, from combined therapies using radiation 
and chemotherapy following surgery, commonly used for the advanced-stage disease 
to single-modality therapy, such as radiotherapy, chemotherapy or surgery alone, 
which are usually applied to early-stage disease (Noguti et al., 2012). 
As any cancer, OSCC is caused by genetic and epigenetic alterations, often 
spontaneous but increased by chemical mutagens (frequently present in tobacco). The 
various changes in the DNA can progress from a normal keratinocyte to a potentially 
malignant keratinocyte that is characterized by an ability to proliferate in a less-
controlled fashion than normal. The cells become autonomous and true cancer results, 
characterized by invasion across the epithelial basement membrane and, ultimately, 
local and distant metastasis (Scully and Bagan, 2009). Clearly, the disease develops 
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over many years and during this period there are several sites where cancer may 
transform and take place in the oral cavity (Tanaka and Ishigamori, 2011). The theory 
of “field cancerization” stated that cancer does not arise as an isolated cellular 
phenomenon but rather as an anaplastic tendency involving many cells at once. 
Exposure to carcinogens results in an altered field in which the epithelium has multiple 
independent foci of abnormal tissue that can subsequently give rise to premalignant 
and malignant lesions. It has been frequently used to explain the occurrence of multiple 
primary cancers and recurrences following complete excision of oral cancer (Angadi et 
al., 2012). 
The host response to evolving cancer cells results in the generation of tumor 
tissue that contains components of normal organs. Such robust host responses define 
complex heterotypic interactions of cancer cells with host cells and are known as 
desmoplastic reaction, tumor stroma or tumor microenvironment (TME) (Kalluri et al 
2016). The “seed and soil” hypothesis postulates that an appropriate host 
microenvironment (the soil) is needed for the optimal growth of tumor cells (the seed). 
It has been gradually realized that the TME plays an active role in the initiation, 
development, and progression of most solid tumors, and therein, the stroma cells are 
usually associated with high tumor malignancy and poor prognosis (Han et al., 2015; 
Reina-Campos et al., 2017). Many of the “hallmarks of cancer” are related to the TME, 
including the ability to induce proliferation and inhibit apoptosis, to induce angiogenesis 
and avoid hypoxia, to inhibit the immune system and avoid immune detection, and to 
activate immune cells to support invasion and metastasis (Hanahan and Weinberg, 
2011; Casey et al., 2015). Different types of normal cells make up the TME, including 
fibroblasts, immune cells (such as T lymphocytes, B lymphocytes, natural killer cells 
and natural killer T cells, Tumor-associated macrophages, etc.), as well as pericytes 
and sometimes adipocytes. The stroma cells in TME can secrete growth factors, such 
as hepatocyte growth factor (HGF), fibroblast growth factor (FGF) and CXCL12 
chemokine, which can not only promote growth and survival of malignant cells but also 
function as a chemoattractant that stimulates the migration of other cells into the TME 
(Hui and Chen et al., 2015). Non-cellular components include mainly the extracellular 
matrix (ECM), which is composed of proteins, glycoproteins, and proteoglycans that 
act as a scaffold and maintain the tissue architecture (Reina-Campos et al., 2017). 
Among the supporting cells, fibroblasts represent the majority of the stromal 
cells in various types of human cancers. Fibroblasts associated with cancer have been 
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termed cancer-associated fibroblasts (CAF), tumor-associated fibroblasts, activated 
fibroblasts or activated myofibroblasts (Kalluri, 2016). The origins of CAF are still not 
fully clear. Resolving this problem may be very helpful for understanding the distinct 
traits of CAF with various molecular markers and multiple tumor-promoting 
phenotypes. CAF can be originated from resident fibroblasts, senescent fibroblasts, 
bone marrow-derived mesenchymal stem cells, from other mesenchymal cells within 
TME (adipocytes, vascular smooth muscle cells and pericytes), by epithelial-
mesenchymal transition (EMT) or endothelial-mesenchymal transition (EndMT) (Han 
et al., 2015). Clinical and experimental data indicate that tumor cells secrete a high 
level of transforming growth factor β (TGF-β), which is strongly chemotactic for 
fibroblasts and transdifferentiates them into CAF (Yuan et al., 2016). One interesting 
feature of the carcinogenesis process is that the tumor mass, especially solid tumors, 
hijacks the body’s wound healing process to support their own growth and proliferation. 
By regulating matrix remodeling, angiogenesis and EMT (the same mechanisms 
necessary for the normal wound healing process), CAF effectively promote 
tumorigenesis and metastasis. CAF essentially drive the growth and proliferation of 
tumor cells by providing them the necessary growth factors, cytokines and chemokines 
(Roy and Bera, 2016). 
Whereas mature fibroblasts exhibit thin, wavy and small spindle morphology, 
CAF are often described as immature fibroblasts and appear as large, plump spindle-
shaped cells with prominent nucleoli (Gascard and Tlsty, 2016). In general, CAF 
upregulate the expression of alpha smooth muscle actin (α-SMA), which is the most 
widely used marker, along with fibroblast-specific protein 1 (FSP-1/S100A4), platelet-
derived growth factor receptor (PDGFR)-α/β, fibroblast activation protein (FAP), 
urokinase-type plasminogen activator (uPA), periostin, tenascin-C (TN-C), palladin, 
podoplanin, and natriuretic peptide B (NPPB). Evidence also suggest that some 
molecules are specifically downregulated in CAFs, such as caveolin-1 and laminin, 
while epithelial cell markers (cytokeratin) and endothelial cell markers (CD31) are not 
expressed. Despite the numerous markers related in the literature, none of the current 
molecules is uniquely expressed by CAF, and are also found in other stroma cells (Han 
et al., 2015; Gascard and Tlsty, 2016).  
In OSCC, CAF can induce proliferation, migration, invasion, adhesion, and 
EMT, in addition to promotion of angiogenesis, tumor growth in mice and worsen the 
patients’ prognosis. (Kellermann et al., 2007; Kellermann et al., 2008;  Bello et al., 
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2011;  Sobral et al., 2011; Bae et al., 2014;  Li et al., 2014; Zhou et a., 2014; Luksic et 
al 2015; Li et al., 2015; Min et al., 2015; Kayamori et al., 2016; Cirillo et al., 2017; 
Takahashi et al., 2017). Vered et al. (2010) observed that CAF are more common in 
advanced primary metastatic tongue tumors, concluding that they not only promote 
deeper invasion of cancer, but also facilitate metastasis, either by co-metastasizing 
and/or being recruited to lymph nodes (Vered et al., 2010). The possible molecular 
mechanisms are complex and multiple, which can be summarized that CAF could not 
only promote tumor cell proliferation, invasion, and metastasis via direct CAF-tumor 
cell communication, but also enhance several extrinsic tumor promoting processes 
such as angiogenesis, ECM remodeling, and tumor-related inflammation. CAFs are 
likewise important for the clinical behavior of the tumor, thereby becoming a promising 
target (Han et al., 2015). 
The main factor in driving the carcinogenic process lies on the cross-talk in 
the TME between stroma and epithelial cells (Bizzarri and Cucina, 2014). Intratumoral 
communication involves the interplay between cancer cells and noncancer cells within 
the tumor foci, setting the pace for cancer cells to survive, expand, and thrive, even 
under stressful or cytotoxic conditions, potentiating their nonautonomous regulation 
(Han et al., 2017). Additionally, cells may also exchange information through the 
release of extracellular vesicles (EV), able to transfer proteins, receptors, bioactive 
lipids, mRNA and microRNA from the cell of origin to recipient cell that may modify 
their phenotype and function. EVs released from different cell types have been 
recognized as an integral component of the complex network of mediators involved in 
the exchange of biological information among cells within the TME (Camussi et al., 
2013). Additionally, EV can travel through body fluids, thus conveying functional 
information to distant sites in vivo. These findings have completely changed the 
concept of intercellular communication, and have helped to clarify diverse cellular 
processes in pathological and physiological conditions (Minciacchi et al., 2015). 
EV is a general term for membranous vesicles enclosed in a lipid bilayer 
that are released by most cell types into the extracellular milieu, under physiological 
and pathological conditions (Principe et al., 2013; Gopal et al., 2017). Current criteria 
to distinguish between diverse EV populations are based on size, density, subcellular 
origin, function and molecular cargo (Gould and Raposo, 2013). Despite the many 
challenges in EV isolation and characterization, it is now clear that several types of EV 
can be released from a single cell. We are also limited in differentiating one EV 
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population from another to fully study them individually because current methods of 
purification often result in mixtures of particles (Minciacchi et al., 2015). Because of the 
lack of consensus in the literature and aiming a standardization of the nomenclature, 
the International Society for Extracellular Vesicles has encouraged authors to use “EV” 
as a generic term for all secreted vesicles (Gould and Raposo, 2013). When 
categorized, EV are referred to by various names including exosomes, microvesicles 
(or ectosomes), oncosomes and apoptotic bodies (Maas et al., 2017; Han et al., 2017; 
Fujita et al., 2016). Based on intracellular origin or biogenesis, two major classes of EV 
are widely reported: vesicles released through the endosomal pathway (exosomes), 
and by budding from the plasma membrane (microvesicles) (Maas et al., 2017; Verma 
et al., 2015). 
Exosomes are small EV presenting a cup-shaped morphology and ranging 
between 50 and 150 nm in diameter, that originate from the fusion of multivesicular 
bodies (MVB) containing intraluminal vesicles. The MVB are shuttled for either 
lysosomal degradation or fuse with the plasma membrane, releasing their contained 
vesicles into the extracellular space (Principe et al., 2013). The biogenesis of 
exosomes is mainly regulated by the machinery of endosomal sorting complexes 
required for transport (ESCRT) or lipid ceramide. The most common exosomal proteins 
are tetraspanins (CD9, CD63, and CD81), heat shock proteins (Hsp60, Hsp70 and 
Hsp90), membrane transporters and fusion proteins (Annexins, GTPases and flotillin), 
and MVB synthesis proteins (Alix and TSG101) (Maas et al.,2017; Fujita et al., 2016; 
Minciacchi et al., 2015). Furthermore, exosomes contain MVB-associated proteins, as 
well as RNA encapsulated in a lipid bilayer with specific lipid components, such as 
sphingomyelin, cholesterol, ceramide, and glycophospholipid (Fujita et al., 2016). 
Microvesicles are large EV, ranging from 100 to 1000 nm in diameter, 
presenting specific lipid components and enriched in phosphatidylserine. In contrast to 
exosomes, microvesicles bud from the plasma membrane through Arf6- and RhoA-
dependent rearrangements of the actin cytoskeleton, a process that also requires 
increased intracellular calcium and altered membrane asymmetry (French et al., 2017; 
Han et al., 2017). This process can regulate the inclusion of proteins such as major 
histocompatibility complex (MHC) class I, β1 integrin receptors, vesicle associated 
protein 3 (VAMP3) and membrane type 1 matrix metalloproteinase (MT1MMP) 
(Minciacchi et al., 2015). Despite differences in biogenesis and molecular content, the 
distinction between exosomes and microvesicles remains subtle: there is no evidence 
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of a strict separation of their functional roles, and there are no established properties 
or molecular markers which can clearly distinguish these two classes of vesicles 
(Principe et al., 2013). 
Whether EV participate in normal physiological regulation or promotion of 
pathological processes is dependent on their cargo (Qian et al., 2015). Cancer cell-
derived EVs promote angiogenesis and coagulation, modulate the immune system, 
and remodel surrounding parenchymal tissue, which together supports tumor 
progression (Becker et al., 2016). Tumor-derived EV can alter the homeostasis of the 
TME by directly targeting fibroblasts, endothelial and immune cells or by altering the 
structure and composition of the ECM (Minciacchi et al., 2015). Clinically, circulating 
exosomes and microvesicles isolated from cancer patients have been associated with 
metastasis or relapse, and therefore could serve as important diagnostic and 
prognostic markers as well as therapeutic targets (Lener et al., 2015). Prior to 
metastatic spread, EV have been shown to prime distant organs (future metastatic 
sites) towards a conductive microenvironment (i.e. pre-metastatic niche) that facilitates 
survival and outgrowth of incoming tumor cells (i.e. metastatic niche) (Gopal et al., 
2017).  
Tumor-derived EV have shown relevance also in OSCC. Exosomes from 
OSCC cells under hypoxia (rich in miR-21) or normoxia could increase proliferation, 
migration, and invasion of cancer cells in an HIF-1α and HIF-2α-dependent manner (Li 
et al., 2016a), and through the activation of the PI3K/Akt, MAPK/ERK, and JNK-1/2 
pathways in vitro, which also increased the growth rate of tumor xenografts in nude 
mice (Sento et al., 2016). The Akt and ERK pathways were shown to be activated by 
exosomes from a highly metastatic human oral cancer cell line, inducing cell growth 
and motility in a poorly metastatic cancer cell line through the transfer of miR-342-3p 
and miR-1246 (Sakha et al., 2016). In addition, Dickman and collaborators (2017) 
observed an accumulation of intracellular miR-142-3p after the inhibition of exosome 
export protein Rab27A, causing a decrease in TGFBR1 expression in donor cells and 
a reduction of malignant features such as growth and colony formation. Conversely, 
increased excretion of miR-142-3p via donor cell EV and uptake by recipient 
endothelial cells was found to reduce TGFBR1 activity and cause tumor-promoting 
changes in these cells in vitro and in vivo (Dickman et al., 2017). In a recent study, we 
found that EV derived from different OSCC cell lines may promote both pro- and 
antiangiogenic effects. SCC-15 cell-derived EVs promoted a pronounced angiogenic 
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response as well as high apoptosis and cellular migration of endothelial cells, whereas 
EV secreted by the more invasive HSC-3 cell line showed opposite effects. These 
results not only increase our understanding of the interactions between tumor-derived 
EV and endothelial cells but may also contribute to future investigations on EV and to 
the evolution of therapies that use EVs as targets (Andrade et al., 2017). Clinically, EV 
isolated from the saliva of OSCC patients were rich in proteins related to the 
inflammatory system, transport of metals, cell growth and proliferation (Winck et al., 
2015). 
By transferring content from tumor cells to non-cancerous cells, tumor EV 
potently influence recipient cell behavior and promote the development of an 
environment hospitable toward cancer growth, invasion and metastasis (Becker et al., 
2016). In the TME, EV mediate heterotypic interactions between stromal and cancer 
cells to support fundamental cancer hallmarks such as evasion of growth suppressors, 
resisting cell apoptosis, sustained proliferative signaling, evasion of immune 
destruction, and induction of migration, invasion, and angiogenesis (Gopal et al., 
2017). Altogether, EV secreted by tumor and TME cells may instigate a functional 
pathway, favoring cancer progression (Han et al., 2017). Proteomic studies of the 
stroma associated with pancreatic ductal adenocarcinoma (PDAC), discovered that 
CAF-derived annexin A6 (ANXA6)+ EV carrying the ANXA6, low-density lipoprotein 
receptor-related protein 1 (LRP1), and thrombospondin 1 (ANXA6/LRP1/TSP1) 
complex, markedly improve cancer cell survival and migration, while ANXA6 depletion 
in CAF abrogates complex formation and reduces PDAC aggressiveness including the 
metastatic potential (Leca et al., 2016). Tumor cell derived EV containing transforming 
growth factor 𝛽 (TGF-𝛽) can drive fibroblast differentiation into CAF in prostate cancer 
(Webber et al., 2015). Interestingly, EV purified from fibroblasts isolated from OSCC 
patients were found to be enriched in TGF-𝛽RII, and the transfer of these EV increases 
TGF-𝛽 signaling in SCC keratinocytes that are nonresponsive to TGF-𝛽 ligand in the 
absence of EV transfer (Languino et al., 2016). Thus, TGF-𝛽 signaling can be 
influenced by the mutual crosstalk between cancer cells and the adjacent 
microenvironment, a mechanism that potentially promotes therapy resistance in 
multiple cancer types (Han et al., 2017). Despite these findings, and given the 
relevance of CAF in the TME, little is known about the role of CAF-EV in oral cancer 
cell progression. 
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As stated before, the TME is actively remodeled and reprogrammed by 
CAF. Secretory functions mediate immune reprogramming, self-sustained activation 
and engage cancer cells, promoting or restraining their growth, survival or resistance 
to therapy (Kalluri et al., 2016). Identifying proteins synthesized by CAF is crucial for a 
better understanding of the biological events associated with oral tumorigenesis and 
for the discovery of new tumor biomarkers, enabling, for example, discrimination of 
patients at high and low risk of developing metastasis and allowing for more 
individualized treatment (Bagordakis et al., 2016). Through RNA screening, 
bioinformatics tools and confirmation by immunohistochemistry from the Human 
Protein Atlas, Bozóky et al (2013) identified the ROCK2 oncoprotein to be expressed 
in CAF but not in normal fibroblasts, which is linked to the Rho kinase signaling 
pathway. This pathway is believed to be responsible for regulating the actin 
cytoskeleton, cell adhesion, and cell migration and is therefore also partially 
responsible for the myofibroblastic phenotype seen in CAF. This pathway also includes 
α-SMA, generally used as a CAF marker. Rho kinase signaling has been associated 
with increased tissue stiffness, which in turn contributes significantly to tumor cell 
survival, proliferation and progression (Bozóky et al., 2013). 
ROCK2 is an oncoprotein with important roles in tumor proliferation, 
apoptosis, adhesion, migration and invasion, and its overexpression has been reported 
in tumor cells from hepatocellular carcinomas (Wong et al., 2015), pancreatic 
adenocarcinomas (Rath et al., 2017), colorectal cancers (Qiu et al., 2015), gastric 
cancers (Li et al., 2016b), breast carcinomas (Hsu et al., 2015), esophageal cancers 
(Wang et al., 2016), renal cell carcinomas (Xu et al., 2016) and oral cancers (Jiang et 
al., 2010). In most of those studies, overexpression of ROCK2 has been related to 
tumor progression, metastasis and poor clinical outcome (Hsu et al., 2015; Li et al., 
2016; Qiu et al., 2015; Rath et al., 2017; Wang et al., 2016; Xu et al., 2016). In OSCC, 
the enhanced expression of ROCK in highly metastatic oral tongue SCC cells 
increased the activity of Rho GTPase signaling cascade, which promoted cancer cell 
migration and invasion (Jiang et al., 2010). However, the prognostic value of the 
tumoral expression of ROCK2 in OSCC, and its correlation with CAF density has not 
been accessed up to date. 
Based on the current stage of knowledge, the general aim of this study was 
to better understand the role of CAF in OSCC, and specifically: 1) to assess, through 
systematic review and meta-analysis, the potential of CAF density 
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(immunohistochemical detection of α-SMA-positive fibroblasts) as prognostic marker 
for OSCC; 2) to determine the role of EV released by CAF in invasion, migration, 
proliferation, and viability of different OSCC cell lines; and 3) to evaluate the prognostic 
relevance of ROCK2 tumor expression in OSCC patients and its correlation with CAF 
density. 
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Abstract 
Aim: To perform a meta-analysis to assess whether the presence of cancer-
associated fibroblasts (CAF) is a prognostic marker of oral squamous cell carcinomas 
(OSCC). 
Methods: Immunohistochemical studies assessing the prognostic relevance of CAF 
(alpha smooth muscle actin (α-SMA)-positive fibroblasts) in patients with OSCC were 
systematically reviewed using Cochrane, Lilacs, PubMed, Scopus and Web of Science 
databases. The outcomes assessed were overall survival (OS) and disease-free 
survival (DFS). The meta-analysis was performed using the random and fixed effects 
model with an adjusted hazard ratio (HR) and 95% confidence intervals (95% CI) as 
effect measures. The methodological quality of the included studies was assessed 
using the Meta-Analysis of Statistics Assessment and Review Instrument (MAStARI) 
tool and the evidence quality was assessed by the Grading of Recommendation, 
Assessment, Development, and Evaluation (GRADE) system. 
Results: The presence of high levels of CAF in the stroma of OSCC predicted reduced 
DFS (HR= 3.32, 95% CI: 2.09-5.26, p<0.00001) and an overall decrease in survival 
(HR: 2.16, 95% CI: 1.60-2.92, p<0.00001). Moreover, increased presence of CAF was 
frequently reported in association with parameters that worsen the prognosis in OSCC, 
including advanced disease stage (TNM classification), recurrence, tumor grade, depth 
of invasion, vascular, lymphatic and neural invasion and extranodal metastatic spread. 
Conclusion: The presence of CAF, as assessed by α-SMA-positive fibroblasts in the 
stroma, indicates poor prognosis in patients with OSCC. 
 
Keywords: oral cancer; cancer-associated fibroblast; alpha smooth muscle actin; 
prognosis. 
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Introduction 
Oral cancer, representing more than 90% of cases of oral squamous cell 
carcinomas (OSCC), is the eleventh most commonly diagnosed cancer worldwide, 
accounting for 300,000 new cases and 145,000 deaths per year (1). The prognosis of 
OSCC is widely variable, depending largely on clinical stage (TNM classification) and 
localization in the oral cavity. Overall, the 5-year survival rate is approximately 50%, 
which has remained unchanged over recent decades (2). Although advances in 
molecular biology have helped identify and characterize genes and molecular 
pathways involved in development and disease progression, little impact on predicting 
disease behavior, prognosis and treatment response has resulted (3). Therefore, 
markers for early detection, differentiating low and high-risk groups, personalizing 
treatment plans and post-therapeutic monitoring are urgently required. 
During OSCC invasion, tumor cells induce a series of modifications in the 
adjacent stroma, promoting a unique environment (commonly termed the tumor 
microenvironment) composed of an extracellular matrix scaffold, vascular structures 
and cellular components including adipocytes, muscle cells, mast cells, immune and 
inflammatory cells and fibroblasts. Some fibroblasts acquire an activated phenotype 
and are termed cancer-associated fibroblasts (CAF; also known as peritumoral 
fibroblasts, activated fibroblasts or myofibroblasts) (4). CAF are thought to have a 
variety of origins, including transformation from resident fibroblasts, epithelial cells and 
pericytes or differentiation from mesenchymal stem cells (5). There is no specific 
marker for CAF, but alpha smooth muscle actin (α-SMA) is the most used and reliable 
marker for detecting CAF (6). CAF are found in approximately 60% of OSCC, 
frequently in close contact with the tumor islands (7, 8), but are not found in tumor-free 
tissues and in the adjacent stroma of potentially malignant disorders of the oral mucosa 
(9). Moreover, in vitro studies have demonstrated that transforming growth factor beta 
(TGF-β) released by oral carcinoma cells induces CAF activation (8, 10), suggesting 
that the emergence of CAF within tumor microenvironment is influenced by tumor cell 
invasion. 
Previous studies have demonstrated that increased density of CAF in the 
stroma of OSCC correlated with higher mortality (7, 11, 12). Further analyses revealed 
that CAF promote tumorigenesis of OSCC cell lines via an enriched and specific 
secretome, which contains activin A, fibronectin type III domain-containing 1 (FNDC1), 
serpin peptidase inhibitor type 1 (SERPINE1), stanniocalcin 2 (STC2), among other 
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proteins putatively related to tumorigenesis (13, 14). Importantly Marsh and 
collaborators (12) provided evidence that the presence of CAF in the stroma of OSCC 
is a stronger predictor of mortality than the classical TNM staging. However, other 
studies did not find a significant association between CAF and survival of OSCC 
patients (15, 16). The aim of this systematic review and meta-analysis was to verify 
the value of CAF for the prognosis of OSCC patients. The present study provides 
evidence that immunohistochemical detection of CAF (α-SMA-positive cells) is an 
independent marker of shortened disease-free survival (DFS) and poor overall survival 
(OS) in patients with OSCC. 
 
Materials and methods 
This systematic review adhered to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) Checklist as described in Moher et 
al (17). 
 
Protocol and registration 
The review was registered at the international prospective register of 
systematic review (http://www.crd.york.ac.uk/PROSPERO/) and received the number 
CRD42017060787 
(http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017060787). 
 
Study design 
The systematic review and meta-analysis of human studies were 
undertaken to evaluate whether immunodetection of CAF (α-SMA-positive fibroblasts) 
serves as a prognostic factor of the survival of patients with OSCC. 
 
Eligibility criteria 
Inclusion criteria: Articles that assessed the relationship between the 
immunohistochemical presence of CAF and the survival of OSCC patients were 
selected for our systematic review and meta-analysis. The search was conducted 
without time and language restrictions. The PICOS (population, intervention, 
comparison, outcome, study design) format was used to construct the research 
question with the following inclusion criteria: (i) Population: patients with oral squamous 
cell carcinoma (OSCC); (ii) Intervention: CAF analysis by immunohistochemical 
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detection with anti-α-SMA antibody; (iii) Outcome: OS and DFS; (iv) Study Design: 
observational studies in humans. Exclusion criteria: Studies were excluded for the 
following reasons: (1) studies that did not fit PICOS strategy; (2) reviews, letters, 
personal opinions, book chapters and conference abstracts. 
 
Information sources and search strategy 
Search strategies in the Cochrane, LILACS, PubMed, Scopus and Web of 
Science databases included the following terms: "oral squamous cell carcinoma" OR 
"OSCC" OR "oral cancer" OR "oral cancers" OR "mouth neoplasms" (MeSH Terms) 
OR "mouth neoplasm" OR "oral neoplasm" OR "oral neoplasms" OR "cancer of mouth" 
OR "mouth cancers" OR "mouth cancer" OR "cancer of the mouth" OR "tongue cancer" 
OR "squamous cell carcinoma of the oral cavity" OR "tongue squamous cell 
carcinoma" OR "tongue squamous cancer" AND "cancer-associated fibroblast" OR 
"carcinoma-associated fibroblast" OR "CAF" OR "peritumoral fibroblast" OR "activated 
fibroblast" OR myofibroblast OR myofibroblasts. 
The search was conducted on April 02, 2017. A partial grey literature search 
was also performed using Google Scholar and ProQuest. The selected references 
were checked and managed by a reference manager software (EndNote, Thomson 
Reuters, Virginia, USA). In addition, the reference lists of the selected articles were 
hand screened for potentially relevant studies that could have been missed during the 
electronic database searches. 
 
Study selection 
The articles were selected in two phases. In phase 1, two authors (MRD 
and RDC) independently reviewed the titles and abstracts and selected those that 
apparently met the inclusion criteria. In phase 2, the same authors read the full texts 
of the selected articles at phase 1 and excluded those that did not meet the inclusion 
criteria. Any disagreements in the first or second phases were resolved by discussion 
and mutual agreement between the two authors. If the two authors did not reach a 
consensus, a third author (ENSG) made the final decision. 
 
Data collection process and data items 
One author (RDC) collected the following information from the included 
articles: authors, year of publication, country, the number of samples, localization, 
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clinical stage, classification (score system), results and adjusted hazard ratio (HR) and 
95% confidence interval (CI) for both OS and DFS. A second author (MRD) cross-
checked all the retrieved information. Disagreements were resolved by discussion and 
mutual agreement between the authors. When necessary, a third author (ENSG) made 
the final decisions. 
 
Risk of bias in individual studies 
Methodologically, the authors appraised all of the included studies 
according to a checklist based in Meta-Analysis of Statistics Assessment and Review 
Instrument (MAStARI) (18). Two reviewers (MRD and RDC) answered 9 questions for 
descriptive studies as Y for “yes”, N for “no”, U for “unclear” and NA for “not applicable”. 
After that, the risk of bias was categorized as high when the study reached up to 49% 
of a “yes” score, moderate when the study reached 50% to 69% of a “yes” score, and 
low when the study reached more than 70% of a “yes” score. Disagreements were 
solved by discussion between the three authors (MRD, RDC, and ENSG). 
 
Measures for meta-analysis 
The OS and DFS meta-analysis was performed following the appropriate 
Cochrane Guidelines (19). Review Manager 5.3 (Rev-Man 5.3, The Nordic Cochrane 
Centre, Copenhagen, Denmark) was used to construct the forest plots of the meta-
analysis, with the HR and 95% CI determined at a significance level of 5%, based on 
the adjusted OS and DFS original values of the selected articles. 
 
Risk of bias across studies 
We assessed heterogeneity by comparing variability among number of 
samples, localization, clinical stage, classification and outcomes for survival studies 
(HR and 95% CI). 
 
Level of evidence 
The Grading of Recommendation, Assessment, Development, and 
Evaluation (GRADE) instrument (20) was used to assess evidence quality and grading 
of recommendation strength in the 12 studies included in the quantitative synthesis 
(11, 12, 14, 15, 21-28). This assessment was based on the study design, risk of bias, 
inconsistency, indirectness, imprecision and other considerations. Evidence quality 
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was characterized as high, moderate, low or very low. The GRADE was assessed 
using the website http://gradepro.org. 
 
Results 
Study selection 
In the first phase, 374 studies were selected in the five electronic databases. 
Duplicate studies were removed, resulting in 200 different citations. Subsequently, 
comprehensive evaluation of titles and abstracts resulted in the exclusion of 167 
citations, thereby remaining 33 studies for consideration into the second phase. 
Moreover, 15 citations were identified in the grey literature (Google Scholar and 
ProQuest). The expert (RDC) identified 2 additional studies. In the second phase, the 
full-text review was then conducted on the 35 first-phase selected citations, which lead 
to the exclusion of 15 studies. In the end of the two phases, 20 studies fulfilled the 
inclusion criteria, but only 12 articles performed multivariate analysis and made 
accessible the adjusted HR and 95% CI. A flow-chart detailing the processes of 
identification, inclusion, and exclusion of the studies is depicted in Fig. 1. 
 
Study characteristics 
The selected studies were published between 2007 and 2017 and were all 
written in English. They were conducted in 8 different countries: Brazil (7, 8, 14, 25), 
Japan (15, 21, 28), Israel (16, 22, 23), China (24, 26, 29), Finland (30), England (12, 
31), Croatia (27) and Norway (32). In addition, 2 studies were performed in 
collaboration, 1 between Finland and Israel (11) and 1 between Brazil and Finland (33). 
The selected articles were observational studies. The main features and findings of the 
studies are presented in Table 1. 
 
Risk of bias 
Based on the MAStARI assessment, 3 articles (8, 15, 29) were classified as 
carrying a high risk of bias, mainly because the answers for questions 3 and 4 (related 
to confounding factors and outcomes, respectively) were “No”. Sixteen studies were 
classified as with moderate risk for bias (7, 11, 12, 14, 16, 21-24, 26-28, 30-33) and 1 
study was classified as low risk of bias (25) (Table 2). 
With respect to MAStARI question 3, many studies did not include the 
classical prognostic factors associated with OSCC survival in the analysis. Treatment 
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protocol and status of the surgical margins, which is essential for post-surgical therapy, 
were the most common lacking parameters. MAStARI question 4 deals with the criteria 
of the outcomes, including the assessment of the immunohistochemistry. In most of 
the studies, except Kawashiri et al (21), the quantification of CAF was subjective and 
performed by a single examiner, leaving the possibility of great variability. 
Regarding the risk of bias across studies, the selected studies used similar 
methods, which reduced the possibility of misinterpretation. These studies were 
suitable for grouping for meta-analysis, and two different subgroups, based on the 
outcome, were generated. 
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Figure 1. Flow Diagram of literature search and selection criteria adapted from PRISMA (17).
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Table 1. Overview of the immunohistochemistry studies with CAF (α-SMA positive cells) as a prognostic marker of oral squamous 
cell carcinomas. 
Study Year No. of 
Samples 
Localization Clinical 
Stage 
Classification Summary of the Results 
Kellermann et al 
(Brazil) 
2007 83 Tongue All  Negative 
 Scanty (<50%) 
 Abundant (>50%) 
Abundant expression in the tumor 
front associated with N stage, 
vascular, lymphatic and perineural 
invasion and poor OS 
Kellermann et al 
(Brazil) 
2008 34 All All   Similar to Kellermann et al 
(2007) 
Associated with N stage, disease 
stage and cervical relapse of 
disease (regional recurrence) 
Kawashiri et al  
(Japan) 
2009 84 All (including 
lip) 
All  Negative 
 Positive 
Association with tumor grade, mode 
of invasion and lymph node 
metastasis. No association with OS 
at multivariate analysis 
Vered et al  
(Israel) 
2010 50 Tongue All  0 (negative) 
 0.5 (few cells attached to 
tumor islands/nests) 
 1 (few concentric layers in 
several foci) 
 2 (cells in many areas of 
tumor) 
 3 (abundant throughout the 
tumor) 
Association with histological grade 
and DFS (local recurrence) at 
multivariate level. Association with 
OS did not resist to multivariate 
analysis 
Bello et al  
(Finland and 
Israel) 
2011 77 (128 
blocks) 
Tongue All  Poor (negative) 
 Medium (less dense or CAFs 
not distributed throughout the 
entire tumor) 
 Rich (dense distribution 
throughout the tumor) 
Associated with shortened OS at 
multivariate level 
Marsh et al  
(England) 
2011 282 All (including 
lip) 
All  Negative 
 Low (<5%) 
 Moderate (5-50%) 
Associated with depth of invasion, 
extranodal metastatic spread, and 
worse DSS at multivariate level 
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 High (>50%) 
Dayan et al  
(Israel) 
2012 64 Tongue All  0 (negative) 
 1 (weak staining in <50% 
cells) 
 2 (weak staining in >50% 
cells) 
 3 (strong staining in <50% 
cells) 
 4 (strong staining in >50% 
cells) 
Associated with worse DFS and OS 
at multivariate level 
Fuiji et al 
(Japan) 
2012 108 All All  Negative 
 Scanty (small number and 
scattered) 
 Focal (concentrated in an 
irregular and non-continuous 
focus) 
 Abundant (concentrated in a 
continuous focus) 
Lower OS for patients with focal 
classification. No withstood to 
multivariate level 
Ding et al  
(China) 
2014 50 Tongue All  0 (negative) 
 1 (one-layer of cells around 
tumor islands/nests) 
 2 (multilayer of cells in many 
areas of tumor) 
 3 (dense overlapping 
throughout the tumor) 
Associated with tumor stage, lymph 
node metastasis and OS at 
multivariate level 
Dhanda et al  
(England) 
2014 102 All All  Low 
 Intermediate 
 High 
Expression at the invasive front 
associated with lymph node 
metastasis, extracapsular spread in 
the lymph nodes and poor OS 
Almangush et al 
(Finland) 
2014 82 Tongue I and II  Similar to Bello et al (2011) Not associated with survival 
Kelner et al  
(Brazil) 
2015 110 Tongue I and II  Similar to Kellermann et al 
(2007) 
Not associated with survival 
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Li et al (China) 2015 178 Tongue All  Similar to Vered et al (2010) Associated with pathologic stage, T 
stage, N stage, recurrence and OS 
at multivariate level 
Luksic et al 
(Croatia) 
2015 152 All All  0 (negative) 
 1 (<25%) 
 2 (26-50%) 
 3 (51-75%) 
 4 (>76%) 
High scores (2, 3, 4) were 
associated with T stage, presence 
of occult neck metastasis, regional 
recurrence, distant metastasis and 
OS at multivariate level 
Matsuoka et al 
(Japan) 
2015 60 All All  Low (low percentage of 
positive cells and intensity of 
stain, <4) 
 High (high percentage of 
positive cells and intensity of 
stain, ≥4) 
High expression associated with 
pTstage and pN stage. No 
association with OS and DFS at 
multivariate level 
Bagordakis et al 
(Brazil) 
2016 113 All All  Similar to Kellermann et al 
(2007) 
Abundant expression associated 
with relapse (DFS) at multivariate 
level 
Lin et al (China) 2016 86 All All  Negative 
 Weak 
 Moderate 
 Strong 
Associated with histological grade, 
invasive phenotype, lymph node 
metastasis and recurrence 
Akrish et al 
(Israel) 
2016 65 Buccal 
mucosa, 
gingiva, 
palate 
All  Similar to Bello et al (2011) Associated with tumor stage, tumor 
grade, perineural invasion and 
tumor thickness, but not with 
survival 
Sundquist et al 
(Finland and 
Brazil) 
2017 60 Tongue I and II  Similar to Bello et al (2011) Not associated with survival 
Parajuli et al 
(Norway) 
2017 111 All All  Poor (up to 3 concentric 
layers of cells around tumor 
islands) 
 Rich (more than 3 concentric 
layers of cells around tumor 
At invasive tumor front, CAF were 
associated with poor OS at 
univariate analysis 
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Table 2. Analysis of the risk of bias of the articles included in the review was performed with the MAStARI (Meta-Analysis of 
Statistics Assessment and Review Instrument) critical appraisal tool (18). 
 
Studies Questions* % Yes# Risk of Bias 
 Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9   
Kellermann et al (2007) NA Y N N NA Y NA Y N 50 M 
Kellermann et al (2008) NA Y N N NA U NA Y N 33.3 H 
Kawashiri et al (2009) NA Y N Y NA U NA Y Y 66.6 M 
Vered et al (2010) NA Y Y N NA N NA U Y 50 M 
Bello et al (2011) NA Y N N NA Y NA U Y 50 M 
Marsh et al (2011) NA Y Y N NA N NA Y Y 66.6 M 
Dayan et al (2012) NA Y N N NA Y NA U Y 50 M 
Fujii et al (2012) NA Y N N NA U NA U Y 33.3 H 
Ding et al (2014) NA Y N N NA Y NA Y Y 66.6 M 
Dhanda et al (2014) NA Y N N NA Y NA Y N 50 M 
Almangush et al (2014) NA Y N N NA Y NA Y U 50 M 
Kelner et al (2015) NA Y Y N NA Y NA Y Y 83.3 L 
Li et al (2015) NA Y N N NA Y NA U Y 50 M 
Luksic et al (2015) NA Y Y N NA Y NA U Y 66.6 M 
Matsuoka et al (2015) NA Y N N NA U NA Y Y 50 M 
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Bagordakis et al (2016) NA Y Y N NA Y NA U Y 66.6 M 
Lin et al (2016) NA Y N N NA U NA Y N 33.3 H 
Akrish et al (2016) NA Y N N NA Y NA Y U 50 M 
Sundquist et al (2017) NA Y N N NA Y NA Y U 50 M 
Parajuli et al (2017) NA Y N N NA Y NA Y N 50 M 
 
Q1. Is the study based on a random or pseudorandom sample? 
Q2. Are the criteria for inclusion in the sample clearly defined? 
Q3. Are confounding factors identified and strategies to deal with them stated? 
Q4. Are outcomes assessed using objective criteria? 
Q5. If comparisons are being made, was there sufficient description of the groups? 
Q6. Is follow up carried out over a sufficient time period? 
Q7. Are the outcomes of people who withdrew described and included in the analysis? 
Q8. Are outcomes measured in a reliable way? 
Q9. Is appropriate statistical analysis used? 
 
*Y=Yes, N=No, U=Unclear, NA=Not applicable (which was not considered in the percentage calculation) 
 
# Risk of bias was categorized as high when the study reaches up to 49% score “yes”, moderate when the study reached 50% to 69% score 
“yes”, and low when the study reached more than 70% score “yes”. 
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Correlation between CAF and clinicopathological characteristics 
Although there was no standard score system to assess CAF density in the 
stroma of the tumors, all studies reported some positive relationship between the 
presence of CAF and clinicopathological features of tumors. The main findings of each 
study are described in Table 1. CAF were identified in the stroma of OSCC for the first 
time by Barth and collaborators in 2004 (34), but the first study demonstrating their 
prognostic significance in OSCC was reported by Kellermann and colleagues in 2007 
(7). This study analyzed the presence of CAF in 83 squamous cell carcinomas of the 
tongue and revealed that CAF are found both in stroma within the tumor and in the 
deepest invasive tumor front, representing the band of tissue between the invasive 
tumor front and adjacent normal tissue. The high density of CAF in the stroma and in 
the invasive tumor front was significantly associated with clinical N stage, vascular and 
lymphatic invasion pathologically confirmed lymph node metastasis and extracapsular 
lymph node spread (7). At the invasive front, the density of CAF was also associated 
with perineural invasion. The univariate analysis for OS showed that patients with an 
abundance of CAF at the invasive front had significantly poorer OS rate than those 
with negative or low frequency of CAF (7). No association with DFS was observed. 
The same group confirmed in a second study the association between the presence 
of CAF and parameters of OSCC aggressiveness (8). The presence of CAF was 
significantly correlated with N stage, disease stage and cervical relapse of the disease 
after initial treatment. This study also demonstrated that the presence of CAF was 
significantly higher in tumors containing a high number of Ki67-positive tumor cells. 
Kawashiri et al (21) found CAF mainly in highly invasive OSCC, and their 
presence was significantly associated with the mode of invasion, the degree of 
differentiation of tumors and pathologically confirmed lymph node metastasis. Kaplan-
Meier curve showed that CAF were significantly associated with poor survival of the 
patients, but the significance did not withstand multivariate correction analysis for 
confounders. 
A significant association between CAF and a histopathologic risk score 
system for OSCC proposed by Brandwein-Gensler et al (35), which includes a worst 
pattern of invasion, the pattern of lymphocytic infiltration and perineural invasion, by 
Vered et al (22). This study also showed a significant association of CAF with both OS 
and DFS, but at multivariate analysis, only DFS was significantly influenced by the 
density of CAF. 
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Bello et al (11) observed a significantly higher mortality, after adjustment for 
cofactors, in patients with tongue squamous cell carcinoma that had a high density of 
CAF in the stroma. This study did not perform association analysis between CAF 
density and clinicopathological parameters. 
A significant and positive correlation between the density of CAF and depth 
of invasion and extranodal metastatic spread was reported by Marsh et al (12) in a 
cohort containing 282 OSCC. In this study, multivariate analysis revealed an 
independent and significant prediction of OS by CAF density, regardless of disease 
stage. 
Besides CAF quantification, Dayan et al (23) characterized the inflammatory 
infiltrate in the microenvironment of 64 squamous cell carcinomas of the tongue. The 
density of CAF was inversely correlated with the density of the inflammatory infiltrate, 
but positively correlated with a more protumorigenic and anti-inflammatory infiltrate 
composed of regulatory T cells (Foxp3+ cells), tumor-associated macrophages 
(CD163+ cells) and potentially Treg-inducing immune cells (CD80+ cells). Importantly, 
CAF density was significantly associated with high risk of locoregional recurrence 
(DFS) and a decrease in OS at multivariate analysis. 
Fujii et al (15) reported that the presence of CAF is significantly correlated 
with the presence of CD163-positive macrophages in the tumor stroma, but no further 
significant associations with clinicopathological parameters and OS were observed. 
Kaplan-Meier analysis for OS revealed a significantly lower survival rate for patients 
who had a focal distribution of CAF compared with patients who negative/scanty or 
abundant presence of CAF. However, only 13 patients were classified in the group with 
the focal distribution of CAF. 
Ding et al (24) revealed a significant association between high density of 
CAF and presence of cervical lymph node metastasis and higher TNM classification. 
This study also demonstrated a positive and significant correlation between the 
presence of CAF and expression of vimentin, N-cadherin and blood vessel density. In 
the multivariate regression analysis, high CAF density was significantly associated with 
OS, showing this an independent prognostic factor. 
Dhanda et al (31) observed that the presence of CAF at the tumor invasive 
front, but not in the tumor center, is significantly associated with lymph node 
metastasis, extracapsular spread from metastatic lymph nodes, and poor OS at the 
univariate level. No multivariate analysis was investigated. 
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Almangush et al (30) evaluated 82 patients with early stage tongue 
squamous cell carcinoma and did not find any influence of CAF on patients’ survival. 
No association between CAF and the histopathologic risk score system for OSCC 
proposed by Brandwein-Gensler et al (35) was observed. Similarly, Kelner et al (25) 
demonstrated that CAF did not influence the survival of patients with tongue squamous 
cell carcinoma at an early stage. 
In a study with 178 tongue squamous cell carcinomas, Li et al (26) showed 
a significant association between high density of CAF and pathologic stage, T 
classification, N classification, and recurrence. The survival curves showed that the 
frequency and the distribution of CAF were significantly associated with a poor OS and 
DFS, but multivariate analysis showed that the presence of CAF was an independent 
predictor only for shortened OS. 
Luksic et al (27) found that a high density of CAF in OSCC is associated 
with poor OS by multivariate analysis. These authors also demonstrated that the 
presence of CAF in the tumor stroma was significantly associated with T stage, the 
presence of occult neck metastasis, regional recurrence and distant metastasis. 
The study of Matsuoka and collaborators (28) included 60 patients that 
received preoperatively a combination of radiotherapy, based on daily doses of 2 Gy, 
5 times a week, for 15 days, and chemotherapy with S-1, an oral fluorouracil anti-
cancer drug, concurrently administered at a dose of 80, 100 or 120 mg/day according 
to each patient's body surface area for 14 days from the initiation of radiotherapy. In 
this unique group, the presence of CAF was significantly associated with advanced pT 
and pN stages and with OS and DFS by univariate, but not multivariate analysis. There 
was a positive and significant correlation between the densities of CAF and CD163-
positive macrophages in the tumor microenvironment, but the density of macrophages 
was not also associated with survival. 
Bagordakis et al (14) found in the adjusted multivariate analysis that the 
abundant presence of CAF, either at the tumor center or at the tumor front, significantly 
influences locoregional relapse (DFS) of OSCC patients. Significant correlations, as 
revealed by Spearman’s rank test, were observed between the density of CAF and 
type of treatment and between the presence of CAF in the invasive front and the 
development of a second primary tumor. 
In the 86 OSCC analyzed by Lin et al (29), cases with higher histological 
grade, more invasive phenotype, lymph node metastasis, and recurrence showed 
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significantly higher numbers of CAF. In addition, samples with increased numbers of 
CAF demonstrated elevated tumor cell MMP-9 expression, higher peritumoral 
lymphatic vessel density and higher microvessel density. 
Significant associations between CAF and clinical stage, tumor grade, 
perineural invasion and tumor thickness were reported by Akrish et al (15), but the 
association of CAF with survival was not statistically significant. As reported by 
Almangush et al (30) and Kelner et al (25), the study of Sundquist et al (32) showed 
that the presence of CAF was not significantly associated with survival of tongue 
squamous cell carcinoma at an early stage. 
Parajuli et al (32) showed a significant association between tumors with rich 
areas of CAF and poor OS at the univariate level. No multivariate analysis or 
clinicopathological correlations were investigated. 
 
Survival analysis 
Overall Survival: Eleven studies reported data regarding the association 
between CAF levels and OS (11, 12, 14, 15, 21, 23-28). Six studies (11, 12, 23, 24, 
26, 27) found that the presence of CAF is a significant marker for OS. Three studies 
(25, 30, 33) included only samples at an early stage of tumor development (stage 1-
T1N0M0 or 2-T2N0M0) and reported a lack of association between CAF and survival, 
suggesting that CAF are not prognostic indicators of survival in early stage OSCC. The 
adjusted HR + 95% CI derived from multivariate analysis were used for the meta-
analysis. As shown in Fig. 2, the pooled HR was 2.16 (95% CI: 1.60-2.92, P for 
heterogeneity = 0.02, I2 = 52%), indicating that high levels of CAF is an independent 
prognostic factor for shortened OS. 
Disease-Free Survival: Four studies were evaluated for DFS (14, 22, 23, 
28). As shown in Fig. 3, the pooled HR derived from multivariate analyses was 3.32 
(95% CI: 2.09-5.26, P for heterogeneity = 0.50, I2 = 0%), indicating that patients with a 
high density of CAF demonstrated worse DFS. Three of the studies (14, 22, 23) found 
a significant association between density of CAF and increased relapse of disease 
after initial treatment. 
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Level of evidence 
Based on GRADE analysis, the quality of the evidence for both OS and DFS 
studies was moderate, suggesting a moderate confidence in estimating the outcomes. 
The moderate risk of bias in most studies was the main factor responsible for the 
limited quality of evidence (Supplementary File 1). 
 
 
Figure 2. The high density of CAF is significantly associated with shortening overall 
survival (OS). (A) Forest plot of the hazard ratio for overall survival (OS) comparing 
patients with high presence of CAF in the tumor stroma compared with those with low 
presence. The meta-analysis revealed that CAF was associated with worse OS (HR: 
2.16, 95% CI: 1.60-2.92, p<0.00001). The diamond represents the pooled HR 
performed by the random-effect model. (B) Funnel plot of the studies used in the 
comparison of CAF density for OS. 
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Figure 3. The density of CAF is an independent risk factor for relapse of the disease 
(disease-free survival-DFS). (A) Forest plot for DFS comparing the low and high 
density of CAF. The high presence of CAF in the stroma of OSCC significantly 
predicted shortened time to DFS (HR= 3.32, 95% CI: 2.09-5.26, p<0.00001). The 
diamond represents the pooled HR performed by the fixed-effect model. (B) Funnel 
plot of the distribution of the studies used for DFS meta-analysis. 
 
Discussion 
The biological properties and functions of CAF in tumor progression and 
metastasis have been extensively reported in several studies (4-6, 36-38). Owing to 
the substantial weight of evidence indicating a pro-tumourigenic role, CAF have been 
suggested as a promising therapeutic target in various cancers. However, data on the 
prognostic value of CAF are limited, particularly in OSCC. In the current study, we 
systematically reviewed and meta-analyzed the literature to verify the association of 
CAF with clinicopathological features and survival of OSCC. We extracted data from 
12 eligible studies comprising 1328 patients and pooled data for analysis. The 
combined results showed that CAF predicted poor OS and shortened DFS in OSCC 
patients. In addition, the presence of CAF in the stroma of the tumors was consistently 
associated with several clinicopathological features associated with tumor 
aggressiveness, including tumor stage, tumor grade, recurrence and histological 
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features such as depth of invasion, vascular, lymphatic and neural invasion and 
extranodal metastatic spread. Furthermore, heterogeneity assumption tested by I2 
metric and publication bias examination illustrated the robustness of our results, 
supporting CAF immunodetection as a biomarker for OSCC prognostication. 
Consistently, 3 studies (25, 30, 33) that included early stage OSCC did not 
find any association with patient survival. As extensively reviewed by Kelner et al (25) 
and Sundquist et al (33), the activation (transformation from resident fibroblasts or 
other cells of the stroma) is dependent on the cross-talk with tumor cells during the 
invasion. CAF are not found in the stroma of normal oral mucosa and dysplastic lesions 
(7, 9, 39), but are found in close contact with tumor islands (7, 8, 11, 22). Furthermore, 
in vitro studies demonstrated that cytokines and other factors released by oral 
carcinoma cells induce CAF activation (8, 10), suggesting that the emergence of CAF 
within tumor stroma is coordinated by tumor cell invasion. In support, a meta-analysis 
of the available data showed that larger tumors (T2-T4, >2 cm) have a significantly 
higher density of CAF compared with tumors classified as T1 (<2 cm) (81.7% of high 
CAF for T2-T4 vs. 18.3% for T1; p<0.0001). Taken together, the results indicate that 
immunodetection of CAF might not have prognostic value for OSCC at an early stage 
of development. Due to the limited sample size, large-scale studies including tumors 
at an early stage are still warranted to confirm those results. 
We have found few studies investigating the prognostic significance of CAF 
in other cancer types by meta-analysis. Folgueira and colleagues (40) pooled 1408 
breast cancer cases from 8 studies and showed that CAF expressing matrix 
metalloproteinase 13 (MMP13) and lectin galactoside-binding soluble 1 (LGALS1) are 
positively associated with enhanced OR for axillary metastasis, one of the main 
prognostic factors in breast cancer, whereas CAF expressing caveolin 1 (CAV1) were 
negatively correlated with lymph node metastasis. In a meta-analysis mixing different 
solid tumors (breast cancer, colorectal cancer, esophageal cancer, gastric cancer, liver 
cancer, non-small cell lung cancer, oral cancer, pancreatic cancer and prostate 
cancer), Liu et al (41) found that the abundant presence of CAF in the stroma is 
associated with both poor OS and DFS. Notably, this meta-analysis included studies 
with different entities, increasing the probable selection bias, which calls for further 
investigations on separate cancer types. To our knowledge, the current study was the 
first meta-analysis to explore the prognostic value of CAF in OSCC, and the findings 
are in line with those previous studies of other cancers. 
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This study has some limitations. First, although against the same clone 
(1A4), antibodies from different companies were used; this may lead to differences in 
the quality and intensity of staining results. Second, no method or cut-off definition has 
been accepted and validated for evaluating CAF density. Indeed, several different 
systems were applied to group tumors containing a low or high density of CAF. Third, 
the sample size was limited and we were obligated to exclude some studies of the 
meta-analysis because they did not perform multivariate analysis or did not report the 
adjusted HR and 95% CI. These could have been estimated from the survival curves, 
but we elected not to do because this approach could induce heterogeneity and bias 
in the results. Fourth, the clinical heterogeneity across the studies, including 
differences in tumor site, tumor stage, and other clinicopathological features, was 
profound. Furthermore, assessment and adjustment of confounders differed among 
the studies. Finally, although we have adopted random-effects model for OS because 
moderate heterogeneity was detected, the inherent heterogeneity of included studies 
still existed. From a statistical point of view, our data are consistent and provide 
evidence that CAF density is a potential prognostic marker for OSCC, but the results 
should be further expanded, assuming a clear cut-off score. 
In summary, this meta-analysis showed that abundance of CAF is 
correlated with clinicopathological features that reflect aggressiveness and 
dissemination of this disease and, more important, it was associated with worse OS 
and DFS in OSCC, suggesting that CAF analysis can be considered as a useful 
prognostic biomarker and therapeutic target in OSCC. Large well-designed studies 
employing a standard evaluated method are necessary to obtain higher-quality 
evidence. 
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Supplementary Material 
Supplementary File 1. Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) instrument. 
 
Question: “Is carcinoma-associated fibroblasts (CAF) immunoexpression a prognostic factor of survival for Oral squamous cell carcinoma (OSCC)?” 
 
Quality assessment # of 
Sample 
Effect Quality Importance 
# of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision Other 
considerations 
OSCC Relative 
(95% CI) 
Absolute 
(95% CI) 
  
12 Observatio
nal studies 
Serious1 Serious2  Not serious  Not serious  Strong 
association; 
 all plausible 
residual 
confounding 
would suggest 
spurious 
effect, while 
no effect was 
observed; 
dose 
response 
gradient  
1328 Not 
estimable  
Not 
estimable 
⨁⨁⨁◯ 
MODERATE 
We are 
moderately 
confident in 
the effect 
estimate 
CI: Confidence interval 
1. The majority of studies were classified as with moderate risk for bias; 
2. The moderate heterogeneity of studies that reported Overall Survival ( I2 = 52%). 
GRADE Working Group grades of evidence 
 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different 
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
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vitro migration and invasion in cells from oral squamous cell carcinoma 
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Abstract 
Along with the importance of the cancer cells themselves, the tumor 
microenvironment (TME) plays a crucial role in tumor progression. The cancer-
associated fibroblasts (CAFs) are the most abundant cells in the TME of solid tumors, 
and essential for creating a favorable environment for tumor invasion. Hence, crosstalk 
between CAFs and tumor cells is an important step in this process. One of the channels 
for this communication is via extracellular vesicles (EVs), nanometric particles loaded 
with protein and genetic information. In this study, we evaluated the effects of EVs 
derived from CAF in different oral squamous cell carcinoma (OSCC) cell lines. As 
control, EVs from normal oral fibroblasts (NOF) were used. Based on in vitro assays, 
we showed that CAF-EVs significantly induce migration and invasion of OSCC cells 
and promote a disseminated pattern of OSCC cell invasion in the 3D organotypic 
assay. Furthermore, bioinformatics enrichment analysis of EV protein cargo and 
microarray gene expression of EV-treated cancer cells revealed the enrichment for 
pathways involving Glycolysis/Gluconeogenesis (GAPDH, LDHB, PGAM1), Focal 
adhesion (THBS1, ROCK2, COL6A1, COL1A1, ACTB) and Starch and sucrose 
metabolism (AMY1A, GBA). Taken together, our results suggest a significant role of 
CAF-EVs in the induction of migration and invasion in OSCC cells, which are related 
to the activation of metabolic and structural pathways. 
 
Key-words: extracellular vesicles, carcinoma-associated fibroblasts, oral squamous 
cell carcinoma, migration, invasion. 
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Introduction 
Oral cavity squamous cell carcinoma (OSCC) is the sixth most common 
cancer worldwide and represents more than 90% of all malignancies of the head and 
neck, affecting mostly the floor of mouth and tongue (Warnakulasuriya, 2009). Despite 
advances in diagnostics and therapeutics, the survival rate of OSCC has improved 
only by 5 % in the past 20 years, and in general, the 5‐year survival rate still remains 
around 60 % (Chinn et al., 2015). As a solid tumor, the cooperation between cancer 
cells and tumor microenvironment (TME) is essential for OSCC progression, where the 
so-called cancer-associated fibroblasts (CAFs) play a major role (Wu et al., 2017). 
CAFs are the most abundant cell type within the TME and are recognized as fibroblast-
like cells that acquire the ability to express isoform α of the smooth muscle actin (α-
SMA) (Sobral et al., 2011a). These cells are thought to originate either from tissue-
resident fibroblasts, mesenchymal stem cells recruited from bone marrow, or cancer 
cells that underwent epithelial-mesenchymal transition (Kayamori et al., 2016). In 
OSCC, CAFs have been shown to promote tumor cell migration and invasion (Sobral 
et al., 2011b; Min et al., 2016; Zhang et al., 2016, Kabir et al., 2016), proliferation 
(Kellermann et al., 2008), adhesion (Cirillo et al., 2017), TME immunosuppression 
(Takahashi et al., 2017), angiogenesis (Kayamori et al., 2016), and worsen the 
patients’ prognosis (Dourado et al., 2017). 
A major mode of communication between tumor cells and TME components 
is through the secretion of extracellular vesicles (EVs) (Webber et al., 2015). EVs are 
a heterogeneous group of nanometer-sized circulating particles, composed of a lipid 
bilayer containing transmembrane and cytosolic proteins as well as DNA and various 
RNAs (Tkach and Théry, 2016). EVs may carry a common set of components involved 
in their biogenesis and structure, but also several factors to interact with target cells 
(Lo Cicero et al., 2015). It is known that cancer-derived EVs exert complex cross-talk 
effects on neighboring stromal cells, contributing to the formation of pre-metastatic 
niches, promoting angiogenesis, modulating tumor stroma and interfering with immune 
responses (Sadovska et al., 2015; Becker et al., 2016). On the other hand, EVs derived 
from TME cells may also modulate recipient cells, constituting to the formation of a 
highly complex stroma able to modulate the invasive and metastatic potential of the 
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cancer cells. Together, EVs secreted by tumor and TME cells may instigate a functional 
pathway, favoring cancer progression (Han et al., 2017). 
CAF-derived EVs (CAF-EVs) are shown to promote the migration of breast 
and pancreatic cancer cells (Richards et al., 2017; Leca et al., 2016, Luga et al., 2012), 
and favour the therapy resistance of breast (Sansone et al., 2017), pancreas and 
colorectal cancers (Hu et al., 2015). Additionally, CAF-EVs are able to induce 
epithelial-mesenchymal transition of prostate cancer cells (Josson et al., 2015). 
However, so far little is known about the role of CAF-EVs in oral cancer progression. 
In this study, we show that CAF-EVs interact with OSCC cells and are able to stimulate 
their invasive potential. 
 
Material and Methods 
Cell cultures 
Five CAF and 5 normal oral fibroblast (NOF) cell lines were established 
respectively from OSCCs and healthy oral mucosa, as previously described (Sobral et 
al., 2011b). CAF were isolated from histologically well-differentiated OSCCs, located 
on the floor of the mouth or lateral border of the tongue. Cells were cultured in 
Dulbecco's modified Eagle's media (DMEM, Invitrogen, USA) supplemented with 10% 
fetal bovine serum (FBS, Invitrogen, USA) and antibiotics at 37ºC in a 5% CO2 air 
atmosphere. Four human tongue OSCC (OTSCC) cell lines presenting different 
aggressive behavior were used in this study. HSC-3 (JRCB 0623, Japan Health 
Science Research Resources Bank, Osaka, Japan), SAS (JCRB0620), SCC-25 and 
SCC-15 (ATCC cultures, Teddington, UK) cells were cultured in 1:1 DMEM/F-12 
(Invitrogen, Carlsbad, CA, USA) containing 10% FBS (Invitrogen), antibiotics and 0.4 
ng/ml hydrocortisone (all from Sigma-Aldrich, Ayrshire, UK). All cells were cultured in 
a humidified atmosphere of 5% CO2 at 37°C and CAF/NOF were cultured only up to 
the seventh passage.  
This study was approved by the Human Research Ethics Committee from 
the School of Dentistry, University of Campinas, Brazil (protocol number 
65011017.9.0000.5418). 
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Characterization of NOF and CAF cell lines 
Quantitative PCR (qPCR) 
The expressions of α isoform of smooth muscle actin (α-SMA), fibroblast 
activating protein (FAP), stromal cell derived factor-1 (SDF-1), hepatocyte growth 
factor (HGF), and tissue inhibitor of metalloproteinases (TIMP) -1, -2, -3, -4 were 
assessed to characterize CAF and NOF cell lines. Primers were designed with the aid 
of the Primer Express 3.0 software. After choosing the sequences we used the tool 
Basic Local Alignment Search Tool (BLAST) from PubMed to confirm the sequences 
were unique to the target mRNAs. Total RNA was isolated with TRIzol® reagent 
following the fabricant instructions. Quantitative reverse transcription-PCR (qRT-PCR) 
was performed with the StepOne Plus instrument (Applied Biosystems), and amplicons 
were detected by using a fluorescence method (SYBR® Green PCR Master Mix, 
Applied Biosystems). Target genes were analyzed by using standard curves to 
determine relative levels of gene expression, and individual RNA samples were 
normalized according to the levels of PPIA (Peptidylprolyl Isomerase A). Efficiency 
curves were created through serial cDNA dilutions and all primer sequences used in 
this study are described in Supplementary Table 1. 
 
Western Blot 
Western blot analysis was used to evaluate α-SMA in CAF and NOF cell 
lines. Cells were washed with cold PBS and lysed in a buffer containing 20 mM Tris-
HCl pH 8.0, 137 mM NaCl, 10 % glycerol, 2 mM EDTA, and protease inhibitors. After 
centrifugation, protein concentrations were measured using a protein assay according 
to the manufacturer’s instructions (Bio-Rad Protein Assay, Bio-Rad, USA). Thirty μg of 
total proteins per sample were resolved in a 10% SDS-PAGE under reducing 
conditions and transferred onto nitrocellulose membranes. The membranes were 
blocked with 10% non-fat dry milk in PBS containing 0.1% Tween-20, rinsed in the 
same buffer, and incubated for 2 h with the primary antibodies: anti-α-SMA 
(monoclonal anti-human, clone 1A4, Dako, 1:400) and anti-β-actin (clone AC15, 
Sigma-Aldrich,1:30000). The membranes were incubated for 2 h with the secondary 
antibody (APC/Cy7-conjugated anti-mouse, Abcam, 1:1000) and after washing, the 
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protein sign was detected using the UVITEC chamber (Cambridge, UK) under infrared 
light. 
 
Senescence Assay 
The Senescence Detection Kit® (Abcam) was used to measure the 
percentage of senescent cells among the CAF and NOF cultures up to passage seven, 
through the expression of β-galactosidase activity. In a 12-well plate, 3 x 104 cells/well 
were seeded in triplicates and left to attach for 24 h. The cells were then washed with 
PBS and fixed with the fixative solution provided in the kit for 15 min at room 
temperature. The cells were washed twice and incubated with 500 µl of the Staining 
Solution Mix (staining solution, staining supplement, 20 mg/ml X-gal in DMSO) 
overnight at 37ºC under light protection. In the next day, the cells were visualized under 
the inverted microscope and four pictures from each well were taken at a 100x 
magnification. The blue (senescent) cells were counted using ImageJ software. 
 
EV isolation, quantification, and characterization 
EV isolation 
EVs were isolated using a differential ultracentrifugation method (Théry et 
al., 2006), with few modifications. In essence, subconfluent monolayers (2800 
cells/cm2) of CAF and NOF cells were washed twice with PBS and left under serum-
free conditions for 48 h. The conditioned medium (CM) was collected, centrifuged at 
200 g, 4ºC for 10 min, followed by storage at -80ºC until purification. CM was thawed 
on ice and centrifuged at 10.000 g, 4ºC for 90 min to pellet cell debris and large 
particles. The supernatant was collected and centrifuged at 100.000 g, 4ºC for 90 min 
to pellet the vesicles. After air drying EVs were recovered in 100 µl of filtered PBS and 
stored at -80ºC. 
 
EV quantification 
Protein quantification from EVs was obtained using the colorimetric DC 
Protein Assay (BioRad®). After reading the absorbance at 750 nm, the values were 
applied to a standard curve to determine the relative protein quantification as µg/µl. 
Nanoparticle Tracking Analysis (NTA - Nanosight NS300, Malvern, UK) was used to 
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check the size distribution and concentration of the vesicles. Samples were analyzed 
with NTA 2.3 software (NanoSight) and the results are presented as an average from 
three tracking videos of 60 s each. The size distribution, concentration per ml of buffer 
and concentration per amount of producing cells were calculated. 
 
EV characterization 
To evaluate EV morphology and the presence of EV marker CD63 
membrane protein, Immunoelectron Microscopy (ImmunoEM) was applied as 
previously described (Zlotogorski-Hurvitz et al., 2014). Samples were deposited on 
Formvar carbon-coated, glow-discharged grids and incubated in a blocking serum 
containing 1% bovine serum albumin (BSA) in PBS. The grids were exposed to the 
primary antibody against CD63 (1:50, BD Pharmingen, San Diego, CA, USA) for 20 
min, followed by gold conjugated goat anti-mouse IgG (size 10 nm) (1:25, BBI 
Solutions, Cardiff, UK) for 20 min at room temperature. The negative control was 
prepared by omitting the primary antibody. The grids were stained with neutral uranyl 
acetate and embedded in methylcellulose/uranyl acetate and examined in a Tecnai 
Spirit transmission electron microscope (FEI, Eindhoven, The Netherlands). Images 
were captured by Quemesa CCD camera (Olympus Soft Imaging Solutions GMBH, 
Munster, Germany).  
The Exo-Check™ exosome antibody array (System Biosciences, Canada) 
was also used to detect expected protein markers from the EVs preparation. The 
membrane has 12 pre-printed spots and features 8 antibodies for known markers 
(CD63, CD81, ALIX, FLOT1, ICAM1, EpCam, ANXA5 and TSG101) and a GM130 cis-
Golgi marker to monitor any cellular contamination. Following the fabricant instructions, 
300 µg of EVs were prepared in a lysis buffer, vortexed and combined with a binding 
buffer overnight at 4°C. The membranes were then washed and incubated for 2 h in 
the detection buffer Vectastain Elite ABC kit (Vector Laboratories, USA), followed by 
revelation in the  Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific, 
USA). The images were taken using the LAS-3000 Imager (Fujifilm, USA). 
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EV uptake assay 
HSC-3 cells were co-cultured with CAF- or NOF-EVs to visualize their 
interaction. First, cancer cells were labeled with the Vybrant® CM-DiI Cell-Labeling 
Solution (Thermo Fisher Scientific, USA). Briefly, HSC-3 cells were detached using 
trypsin-EDTA solution (Sigma-Aldrich, UK), re-suspended in serum-free medium 
containing 5 µl/ml of labeling solution and incubated for 20 min at 37°C. The cells were 
then washed 3 times in serum-free media and seeded at a concentration of 5 x 104 
cells/cm2. EVs from NOF and CAF were labeled with the EXO-glow™ labeling kit 
(System Biosciences, Canada), following recommendations of fabricant. Labeled EVs 
at concentration of 30µg/well were added to HSC-3 labeled cells and cultured for 24 h 
at 37 °C. The cells were visualized and pictures were taken in a 10x magnification 
using the EVOS® FL Imaging System (Life Technologies, USA) under an excitation of 
650 nm and 550 nm, and merging the signs afterward. The light intensity was 
measured based on the merging of both colors, assuming the yellow spots as the 
interaction between cancer cells (green) and vesicles (red) using the Leica QWin 
Standard V 3.5 microscope. 
 
Cell viability and proliferation assays 
MTT assay (Cell growth determination kit, Sigma-Aldrich, St. Louis, 
Missouri, USA) was used to compare cell viability, and BrdU assay (Cell Proliferation 
ELISA BrdU assays, Roche, Mannheim, Germany) was used to assess cell 
proliferation. In a 96-well plate, five thousand cells (HSC-3 or SCC-25) were seeded 
together with 15 µg/ml of CAF- or NOF-EVs in 100 µl of serum-free medium in six 
replicates and analyzed 48 h later according to the manufacturer’s protocol. 
Absorbances were read using a Victor3V 1420 Multilabel Counter (Perkin Elmer Life 
& Life Technologies, Waltham, MA, USA). 
 
Cell death analysis  
HSC-3 cell necrosis and apoptosis were analyzed in an FACScan™ system 
(BD Biosciences, USA), after 48 h treatment with pooled CAF- or NOF-EVs. To set 
threshold controls in the equipment, HSC-3 cells were induced to death in UV light. 
Five to ten thousand events were acquired for each sample. Briefly, in a 24-well plate, 
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2 x 105 HSC-3 cells were seeded together with 40 µg/ml of EVs in 500 µl of serum-free 
medium. After 48 h incubation, cells were detached, washed in PBS and re-suspended 
in a binding buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, and 
1.8 mM CaCl2) containing annexin V-FITC (1:500, Invitrogen, USA) and 7-AAD 
(20 μg/μl, 7-Amino-actinomycin D, Molecular Probes, USA). After 20 min of incubation 
cells were also stained with propidium iodide (1:50, Sigma) (Zecchin et al., 2011). 
Apoptosis was quantified by flow cytometry as the number of annexin V-FITC-positive 
and 7-AAD-negative cells, and necrosis as the number of 7-AAD-positive and annexin 
V-FITC-negative cells, both divided by the total number of cells. 
 
Horizontal migration assay 
Scratch wound healing assay was used to assess the effect of pooled CAF- 
and NOF-EVs in HSC-3 cells migration, using the Zeiss Cell Observer spinning disc 
confocal (ZEISS, Germany). Starved HSC-3 cells were seeded in a 24-well plate (2 x 
105 cells/well) together with EVs at two concentrations (10 or 30 µg/ml). The cells were 
incubated for 24 h and an empty area (a wound) was created amid confluent cells by 
removing cells using a sterile 1000 µl pipette tip (Sartorius, Göttingen, Germany). After 
washing the wells with PBS, the plate was placed in the microscope and monitored for 
24 h, taking pictures on each hour. The analysis was made using ImageJ software to 
calculate the wound area in percentage, considering the time zero as 100 %.  
 
Invasion assays 
Transwell® inserts (Corning, USA) were used in 24-well plates to assess 
the individual effect of each CAF- and NOF-EVs in cancer cells invasion (HSC-3, SAS, 
SCC-15, SCC-25) through myogel solidified with low-melting agarose (Salo et al., 
2015). Eighty thousand cancer cells/well were plated on top of the inserts together with 
20 µg/ml of each EV preparation in serum-free medium. Complete medium with serum 
was added on the bottom of each well. The plates were incubated for 72 h and the 
cells that passed through the membrane were stained in a toluidine blue solution. After 
eluted in 1% SDS, the absorbance was measured at 650 nm using the Victor3V 1420 
Multilabel Counter (Perkin Elmer Life & Life Technologies, Waltham, MA, USA). The 
analysis was made by subtracting the absorbance of the negative control from that of 
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EV groups. To evaluate the effect of a higher concentration of EVs, HSC-3 cells were 
cultured with 20 or 50 µg/ml of pooled EVs and analyzed as above. 
The 3D myoma organotypic model (Nurmenniemi et al., 2009) was also 
used to study invasion of HSC-3 cells, co-cultured with pooled CAF- or NOF-derived 
EVs. Myoma discs were preincubated at 4 °C for 48 h in 10 % FBS-DMEM, after which 
they were placed in transwells. The discs were pre-treated with 20 µg of CAF-/NOF-
EVs for 4 h. After that, HSC-3 cells (7×105 cells/well) were seeded together with more 
30 µg of each EVs preparation on the discs and allowed to invade into the myomas for 
14 days. The lower chamber was filled with 10 % FBS-DMEM, which was changed 
every three days. The myomas were fixed in 4% formalin solution and prepared for 
regular H&E staining and the analysis was made in pan-cytokeratin (AE1/AE3) stained 
slides. Pictures were taken from the slides, and the invasion depth and area were 
measured using Image J v1.46o (National Institute of Health, Bethesda, MD, USA). 
Negative controls without vesicles were used in all experiments.  
 
cDNA Microarray 
In a 6-well plate, 9 x 106 HSC-3 cells were seeded in each well, together 
with 50 µg/ml of CAF- or NOF-EVs (or negative controls without vesicles), in serum-
free medium. Each well was pre-coated with 500 µl of myogel (Salo et al., 2015) to 
simulate an extracellular matrix. After 36 h incubation, the HSC-3 cells total RNA was 
extracted by Qiagen RNA kit, followed by DNAse digestion (Qiagen, Dusseldorf, 
Germany). An equal amount of each RNA from the replicates were pooled to generate 
three final groups: HSC-3 + CAF-EVs; HSC-3 + NOF-EVs; HSC-3 negative control. 
Affymetrix GeneChip Human Genome U133 Plus 2.0 Arrays were used and the 
experimental procedures were performed according to the Affymetrix GeneChip 
Expression Analysis Technical Manual using 1 µg of total RNA as template. 
Biotinylated cRNA was synthesized by means of the GeneChip 3’IVT Express kit 
(Affymetrix, Santa Clara, CA, USA) according to the manufacturer’s instructions. The 
cRNA was fragmented to 35 to 200 nt, and hybridized to arrays. After streptavidin-
phycoerythrin (Molecular Probes, Eugene, OR, USA) staining the signal was amplified 
by biotinylated anti-streptavidin (Vector Laboratories Inc.) and the second staining with 
streptavidin-phycoerythrin. Finally, the arrays were scanned on GeneChip Scanner 
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3000. The dChip software (Li and Wong, 2001) was used for expression analyses 
(GEO, GSE85435).  
 
Mass spectrometry 
EVs (3 x 108 vesicles) from each cell line were suspended in up to 30 µl of 
urea buffer (50 mM Tris-HCl pH 7.5, 8 M urea, 2 M thiourea, and 1 mM DTT) for protein 
extraction. Samples in urea buffer were sonicated for 5 min at room temperature. The 
protein extracts were reduced, alkylated, trypsin digested and desalted as previously 
described (Winck et al., 2015). Tryptic-digested peptides were dried in a speed-vac 
instrument and identified in an ETD enabled LTQ Orbitrap Velos mass spectrometer 
(Thermo Fisher Scientific, Bremen, Germany) connected to the EASY-nLC system 
(Proxeon Biosystem, West Palm Beach, FL, USA) through a Proxeon 
nanoelectrospray ion source in a data-dependent mode. Peptides were separated by 
a 2–30 % acetonitrile gradient in 0.1% formic acid using an analytical PicoFrit Column 
(20 cm × ID75 μm, 5 μm particle size, New objective) at a flow rate of 300 nl/min over 
220 min. The nanoelectrospray voltage was set to 2.2 kV, and the source temperature 
was 275°C. All instrument methods for the LTQ Orbitrap Velos were run in the data-
dependent analysis (DDA) mode. The full scan MS spectra (m/z 300–1.600) were 
acquired in the Orbitrap analyzer after accumulation to a target value of 1e6. The 
resolution in the Orbitrap was set to r = 60,000. The 20 most intense peptide ions with 
charge states of ≥2 were sequentially isolated to a target value of 5.000 and 
fragmented in the linear ion trap by low-energy CID (normalized collision energy of 
35%). The signal threshold for triggering an MS/MS event was set to 1.000 counts. 
Dynamic exclusion was enabled with an exclusion size list of 500, exclusion duration 
of 60 s, and a repeat count of 1. An activation q = 0.25 and activation time of 10 ms 
was used. 
All datasets were processed using the workflow feature in Proteome 
Discoverer version 1.3 (Thermo Scientific, San Jose, California, USA) following a 
published protocol (Kawahara et al., 2015). MS/MS spectra were searched with 
Sequest engine (version 1.4.0.288) against Homo sapiens database using the 
following parameters: full trypsin digest with maximum one missed cleavage, fixed 
modification carbamidomethyl (+57 on C) and variable modification oxidation (+16 on 
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M).  Precursor mass tolerance was 10 ppm and fragment tolerance was 1.00 Da. The 
resulting data file was load into Scaffold Q+ (version 4.4.3, Proteome Software Inc., 
Portland, OR, USA) to filter and quantitate peptides and proteins. The scoring 
parameters (Xcorr and Peptide Probability) were set to discover a false discovery rate 
(FDR) of less than 1%, using the number of total spectra output from the ScaffoldQ+ 
software. The peptide thresholds were 60 % minimum and Sequest: XCorr scores of 
greater than 1.8, 2.2, 2.5 and 3.5 for singly, doubly, triply and quadruply charged 
peptides, respectively, and the protein thresholds for identification were 90.0% 
minimum and 1 peptide minimum. STRING 10.0 database (Szklarczyk et al., 2015) 
was used for protein networking and Gene Ontology analyses. 
 
Pathway enrichment analyses and network for CAF- vs. NOF-EVs’ proteomic and 
gene data  
Proteins and genes with differing expressions between the CAF- and NOF-
EVs were included in the pathway enrichment analyses. A list containing both proteins 
and genes with statistically significant fold changes (≥1.2 for up-regulation and ≤-1.2 
for down-regulation) or with exclusive expression was imported into the Integrated 
interactome system (IIS; Carazzolle et al. 2014) for the enrichment for Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathways and respective network file. 
The network of proteins and genes was visualized in Cytoscape v2.8.3 (Shannon et al. 
2003, Smoot et al. 2011). The criteria for selecting the Top KEGG pathways to be 
presented were the following: 1) p-value < 0.05, 2) minimum of two genes or proteins 
assigned in a cluster, 3) exclusion of pathways annotated for viral conditions or 
diseases not associated with cancer. 
 
Statistical analysis 
All the experiments were done at least in triplicates. Mann-Whitney U test 
or one-way analysis of variance (ANOVA) with posthoc comparisons based on the 
Tukey's multiple comparisons test were applied using the GraphPad Prism 5 software. 
The level of significance considered was 5 % (p≤0.05). 
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Results 
Characterization of CAF and NOF cell lines 
Cells were tested for the expression of α-SMA, a reliable CAF marker. As 
expected, the CAF group presented higher levels of this marker through qPCR 
(p=0,004; Fig1A) and western blot (Fig. 1B). Among the other putative markers tested 
by qPCR, only TIMP1 showed higher expression in CAF compared to NOF (p=0.001) 
cells. The complete panel of the tested markers is presented in the Supplementary 
Fig.1. The senescence level of these cells, represented by the β-galactosidase activity, 
was similar among all cell lines, varying from 10-17 % (Fig.1C). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Characterization of the primary cell cultures isolated either from tumor or oral 
healthy tissue. The relative expression of α-SMA was higher in CAF when compared to NOF 
cells by qPCR (p=0,004, A) and western blot (B). The senescence of these cells was accessed 
by the expression of β-galactosidase activity, and the bars represent the percentage of positive 
cells (C).  
 
Characterization of CAF and NOF EVs 
The size distribution of the vesicles was similar in CAF- and NOF-EVs, most 
of them being around 100 and 200 nm (Fig. 2A). The concentration of EVs, measured 
by vesicles/ml of conditioned medium (Fig. 2B), varied among the cell lines and did not 
differ between the CAF and the NOF group. Negatively stained EVs revealed varied 
size round- or cup-shaped, bilayer structures, which were mostly distributed as 
isolated, rather than aggregated particles (Fig 2C). Some of these vesicles were 
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positively labeled with an antibody against CD63, a transmembrane protein enriched 
in EVs. A clear background in the Immuno-EM images indicates an absence of sample 
contamination (protein aggregates, for example) or unspecific antibody binding (Fig. 
2C). The samples were also enriched in other EV markers, such as CD81, TSG101, 
FLOT1, and ALIX, showing a slightly higher expression in the CAF group (Fig. 2D). 
 
 
Figure 2. Characterization of EVs derived from CAFs and NOFs. The size distribution was 
based on NTA (Nanosight) measurements and showed that most of them were around 100-
200 nm (A). The EVs concentration based on the initial volume of conditioned medium did not 
show a different pattern between both groups (B). Immunoelectron microscopy revealed round 
shaped particles of varied sizes with a bilayer membrane, showing positivity for the EV-marker 
CD63 (black small dots linked to the surface of the vesicles) from CAF-EVs (a) and NOF-EVs 
(b). The scale bar represents 500 nm. EVs from CAFs (D.a) and NOFs (D.b) were also positive 
for FLOT1, ALIX, CD81, and TSG101 in an antibody array.  
 
Uptake of EVs by OSCC cells and its effect on proliferation and viability 
The internalization of EVs was assessed to verify if the vesicles from both 
sources (CAF and NOF) would be uptaken by HSC-3 cells. When cultured together 
with HSC-3 cells, CAF- and NOF-EVs showed to be internalized by the cancer cells in 
a similar way (p= 0.431; Fig.3A). Cell proliferation and viability were also evaluated in 
co-cultures with EVs. The treatment did not affect the proliferation of HSC-3 and SCC-
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25 cells (Fig. 3B, C). On the other hand, both EVs reduced the viability of HSC-3 (CAF-
EVs p=0.0307; NOF-EVs p=0.0353) and SCC-25 cells (CAF-EVs p=0.0036; NOF-EVs 
p=0.0026) (Fig. 3D, E). A flow cytometry approach based on cell death analysis 
showed no differences in overall cell death (Fig. 3F), but the CAF-EVs increased the 
apoptosis of HSC-3 cells compared to the negative control (p=0.0191; Fig. 3G).  
 
Figure 3. Internalization of EVs, cancer cells proliferation, viability and apoptosis 
experiments. Labeled HSC-3 cells (green) and EVs (red) from CAFs and NOFs were cultured 
for 24 h. Both CAF- and NOF-EVs were internalized similarly by HSC-3 cells (A, p= 0.431). 
The upper pictures show a 100 µm scale bar and for the lower ones, the bar is 50 µm. The 
EVs did not affect HSC-3 (B) or SCC-25 (C) cells proliferation, but both EVs reduced the 
viability of HSC-3 (D; CAF-EVs p=0.0307; NOF-EVs p=0.0353) and SCC-25 (E; CAF-EVs 
p=0.0036; NOF-EVs p=0.0026) after 48 h. In HSC-3 cells, CAF-EVs did not change the overall 
cell death percentage (F) but they induced a higher percentage of apoptosis (G; p=0.0191). 
 
Effects of EVs on OSCC cells migration, invasion, and gene expression levels 
The effects of CAF- and NOF-EVs on the vertical cell migration was 
accessed by culturing them with HSC-3 cells and following their movement into a 
scratched area. HSC-3 cells cultured with more diluted CAF- and NOF-EVs closed the 
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wounds faster than with more concentrated EVs, and the HSC-3 cells migrated fastest 
when co-cultured with 10 g/ml of CAF-EVs at 12 h and 24 h (p<0.05; Fig. 4). 
 
 
Figure 4. Effect of CAF- and NOF-EVs on the horizontal migration of HSC-3 cells. Pooled 
CAF- and NOF-EVs were labeled (red particles in the picture) and added to the scratched 
wounds of HSC-3 cells at 10 or 30 µg/ml concentrations. HSC-3 cells migrated faster when 
cultured with CAF-EVs at 12 h and 24 h (p<0.05). Pictures represent the initial (0 h) and final 
(24 h) views of the wounded areas, delimitated by a white line.  
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To examine the role of these vesicles on cancer cell invasion, isolated EVs 
from each CAF and NOF cell line cells were cultured together with OSCC cells and let 
to invade into a myogel matrix. The CAF-EVs were individually able to induce invasion 
of the more aggressive cell lines, HSC-3 (around 100 times more when compared to 
the negative control; p=0.0079) and SAS (p=0.0317), and also the less aggressive 
SCC-15 (p=0.0485) and SCC-25 (p=0.066) cells (Fig. 5A, B). When the vesicles were 
pooled into CAF or NOF group, the invasion was still induced in HSC-3 cells (Fig. 5C; 
p=0.0029), but the statistical significance was lost when the EVs were added in a 
higher concentration (Fig. 5D; p=0.172). Since the HSC-3 cells showed the highest 
invasion rate when cultured with CAF-EVs, these cells were also tested in a 3D myoma 
organotypic model (Fig. 5E) The HSC-3 cells cultured with CAF-EVs exhibited a larger 
invasion area when compared to the HSC-3 control (p=0.0417, Fig. 5Ea). The cells 
were also invading deeper after adding CAF-EVs compared to NOF-EVs (p=0.0025) 
or without added EVs (p<0.0001; Fig.5Eb). Likewise, the CAF-EVs group produced 
more tumoral cell islands compared to control (p=0.0155; Fig 5Ec), and the islands 
were smaller in size when compared to the NOF-EVs group (p=0.0043) and to the 
negative control (p=0.0476; Fig. 5Ed).  
In order to analyze the effects of EVs on HSC-3 cells, cDNA microarray was 
applied to the treated cells, using non-treated HSC-3 cells as negative control. The 
resulting gene lists from each group were compared to each other, and normalized by 
the gene expression in the control group, considering a fold-change cutoff ≥1.2. The 
final list of differentially expressed genes among the treatments was generated (see 
the Supplementary Table 2).  
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Figure 5. Invasion in vitro assays of OSCC cell lines treated with CAF- or NOF-EVs. CAF-
EVs from each of the five cell lines were individually able to induce the Myogel coated transwell 
invasion of HSC-3 (p=0.0006), SAS (p=0.0161) and SCC-15 (p=0.0485) cells compared to 
NOF-EVs (A), which is shown in the representative figures of the invaded cells (B). Pooled 
CAF-EVs were able to induce higher invasion rate of HSC-3 cells in 20 µg/ml (C; p=0.0029), 
but the significance was lost at 50 µg/ml (D; p=0.172). Results are given as fold-changes as 
compared to control in which EVs were not added. In the 3D organotypic myoma disc invasion 
assay (E), pooled CAF-EVs induced HSC-3 cells to form larger invasion areas when compared 
to the control (a, p=0.0417), and the cells were invading deeper compared to NOF-EVs 
induced (b, p=0.0025) or non-treated control HSC-3 cells (b, p<0.0001). Likewise, the CAF-
EVs produced more cancer cell islands compared to control (c, p=0.0155), and the cell islands 
were smaller in size compared to the NOF-EVs treated cells (d, p=0.0043) or to the control 
HSC-3 cells (d, p=0.0476). Pictures show pan-cytokeratin AE1/AE3 staining of the HSC-3 
cells, and the scale bars represent 700 µm. 
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EVs protein content 
In order to check the protein content of the EVs derived from CAFs and 
NOFs, we made a proteomic analysis. A total of 141 proteins, with 83 common proteins 
in CAF- and NOF-EVs, and 11 exclusive proteins in the CAF group were identified. 
The Supplementary Table 3 presents the list of differentially expressed proteins, 
including the exclusive and up- or downregulated in CAF-EVs considering a fold-
change cut-off ≥2. Gene Ontology (GO) analysis revealed that the differentially 
expressed proteins were mostly related to immune system process (GO.0002376), 
defense response (GO.0006952), vesicle-mediated transport (GO.0016192), and 
wound healing (GO.0042060). Around 86 % were from the extracellular region part 
(GO.0044421), and almost 80 % were vesicle-related proteins (GO.0031982).  
 
Pathway  enrichment analysis  
The final lists of differentially expressed genes were combined with the 
differentially expressed proteins from EVs to access their interaction and enrichment 
for cancer-related pathways. The top KEEG pathways annotated for that interaction 
were Glycolysis/Gluconeogenesis (GAPDH, LDHB, PGAM1), Focal adhesion (THBS1, 
ROCK2, COL6A1, COL1A1, ACTB), and Starch and sucrose metabolism (AMY1A, 
GBA) (Figure 6). 
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Figure 6. Network on protein and gene KEGG annotations in CAF- vs. NOF-EVs. Proteins 
and genes with statistically significant fold-changes between groups, or exclusive expressions, 
were visualized as respect to their annotated KEGG processes. Processes are presented 
according to their statistical significances starting from the left with the highest statistical 
significance. Proteins are indicated in red and genes in blue. The nodes in the middle of the 
network were not annotated into any KEGG processes or did not fill the criteria for interesting 
Top KEGG pathways. 
 
Discussion 
In oral cancer, CAF are a major participant in the crosstalk between 
carcinoma cells and TME. Here we isolated fibroblast cell lines from human oral cancer 
tissue samples and distinguished CAF from  NOF population. From both cell lines, EVs 
were isolated, characterized and their interactions with different OSCC cell lines were 
analyzed. We showed that CAF-EVs induced migration and a disseminated, budding-
type pattern of OSCC cells invasion in a 3D organotypic assay. Based on 
bioinformatics enrichment analysis, data derived from microarray gene expression of 
EV-treated cancer cells and protein cargo of CAF- and NOF-EVs, we showed the 
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enrichment for three pathways: Glycolysis/Gluconeogenesis, Focal adhesion and 
Starch and sucrose metabolism. Our results suggest a significant role of CAF-EVs in 
the migration and invasion of tumor cells, associated with the expression of genes 
involved in metabolic and structural pathways. 
CAFs constitute the main component of TME and are typically characterized 
by mesenchymal markers, such as α-SMA (Bush and Landberg, 2015). We used α-
SMA to successfully distinguish CAF from NOF. Besides α-SMA, CAFs expressed 
higher mRNA amounts of TIMP1, a member of the tissue inhibitor of 
metalloproteinases family, when compared to NOFs. In consonance, upregulation of 
TIMP1 was shown to induce a transformation of normal liver fibroblasts into CAFs 
(Zheng et al., 2016) and to stimulate the accumulation of CAFs within prostate and 
colon cancer tissues (Gong et al., 2013). The other members of the family, TIMP2, -3 
and -4, were also tested but no differences were found between groups. Similarly, 
SDF-1, HGF, and FAP failed to separate CAFs from NOFs. It is well accepted that 
CAFs represent indeed a heterogeneous cell population, and the expression of 
different markers, alone or in combination, possibly reflect the cell of origin, the 
activation state and the tumor-promoting properties of the cells (Prime et al., 2017).  In 
addition to those markers, senescence was accessed through the expression of β-
galactosidase activity, and the positivity was under 17% of all primary cells. To avoid 
the senescence-associated secretory phenotype (SASP), NOFs and CAFs were 
cultured up to the seventh passage in the experiments reported here. In fact, the tumor-
promoting activity of CAFs is partially mediated through an altered expression profile 
that overlaps significantly with the SASP, and it has been argued that senescent cells 
are actually an operational subtype of CAFs (Alspach et al., 2013). 
There is currently no consensus on a “gold standard” method to isolate 
and/or purify EVs (Lotval et al., 2014). Nevertheless, most studies of EVs from cell 
culture have employed differential centrifugation to concentrate and partially purify EVs 
(Witwer et al., 2013). Either endogenous or exogenous factors can change the content, 
number, and type of cancer-associated EVs, thereby substantially altering their 
activities (Han et al., 2017). Here, the size and concentration of the EVs were similar 
in CAF and NOF population.  In an analogous comparison, Richards et al (2017) found 
similar amounts of EVs from pancreatic ductal adenocarcinoma CAFs and wild-type 
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fibroblasts. Studies showing a higher yield of EVs comparing cancer cells with healthy 
cells were under hypoxia or low pH conditions, known to be cancer hallmarks (Cesi et 
al., 2016; Han et al., 2017). Leca et al (2016) only found increased secretion of EVs by 
CAFs under physiopathologic culture conditions: co-culture with macrophages, 
hypoxia and with lipid starvation. In the present study, the initial number of cells, tissue 
type of origin, culturing time, supplementation and environment conditions were the 
same for both groups, what can partially explain these findings. 
EVs is a general term for a heterogeneous group of cell-derived vesicles 
enclosed by a lipid bilayer which are, depending on their origin, 30–2000 nm in 
diameter (Gudbergsson et al., 2016). Based on intracellular origin or biogenesis, two 
major classes of EVs are reported: exosomes and microvesicles (Verma et al., 2015). 
Exosomes are thought to be around 30-150 nm in diameter and are formed by inward 
budding of endosomal membranes. In turn, microvesicles are larger vesicles ranging 
from 100-1000 nm in diameter, ubiquitously assembled at and released from the 
plasma membrane through outward protrusion or budding (Kalra et al., 2016). Yet, 
categorizing vesicles based on their size or subcellular origin remains problematic 
(Webber et al., 2015). Since there is no consensus on the EVs size distribution and 
our vesicles were mostly around 100-200 nm (which is exactly the overlapping size 
between exosomes and microvesicles), we used the term EVs, following the guidelines 
from the International Society for Extracellular Vesicles - ISEV (Gould and Raposo, 
2013). In the current study, EVs from both NOFs and CAFs were enriched in 
membrane proteins (the tetraspanins CD63 and CD81), and in endosome-associated 
proteins (FLOT1, TSG101, ALIX), known to be enriched in EVs preparation (Cesi et 
al., 2016). Since our samples were negative for GM130, it confirms the absence of 
cellular/organelle contamination. Supposedly different types of EVs may share 
common membrane proteins, and currently, there is still a lack of specific markers to 
clearly distinguish various subpopulations (Yáñez-Mó et al.2015). 
The EV-target cell interaction is the first step of EVs uptake followed by 
fusion or endocytosis (Minciacchi et al., 2015). Different cell types take up EVs using 
various mechanisms resulting in either functional transfer of cargo or degradation of 
their content. The fate may be determined by cell-specific ligands/receptors that “direct 
the conversation” (Abels and Breakefield, 2016). Exosomes may be incorporated 
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through the interaction between heparan sulfate binding proteins on exosomal 
membrane molecules, such as epidermal growth factor receptor (EGFR) and heparin 
sulfate proteoglycans (HSPG), such as syndecan-1 expressed in OSCC cell surface 
(Sento et al., 2016). Our results showed no differences in CAF- or NOF-derived EVs 
internalization by HSC-3 cells after 24 hours. Franzen et al. (2014), observed that the 
uptake of exosomes by bladder cancer cells is dose and time dependent, but saturate 
at around 14 hours of incubation. We demonstrated that higher EVs concentration did 
not stimulate stronger invasion nor migration effects in HSC-3 cells, suggesting a limit 
for uptake or functional effects of the internalized vesicles. 
While the treatment with CAF-/NF-EVs did not alter the proliferation rate of 
cancer cells, both reduced cell viability and CAF-EVs were able to induce higher 
apoptosis events in HSC3-cells.  Santi et al. (2015) observed that CAF-microvesicles 
had a higher effect on prostate cancer cells proliferation than CAF-exosomes. The 
heterogeneous feature of our EVs preparation may have prevented the observation of 
significant differences in cell proliferation between the groups.   
Although CAFs stimulate cancer cell growth, it has been demonstrated that 
these cells have dual functions and also restrict cancer cell growth by inducing 
apoptosis. While monitoring coordinated invasion by gastric cancer cells and CAFs, 
Itoh et al. (2017) observed that a substantial number of cancer cells undergo apoptosis 
due to their coexistence with CAFs. Enhancement of cancer cell apoptosis increased 
CAF-led invasion, which is characterized by dissemination via the movement of 
individual cancer cells away from the tumor. Therefore, CAF-mediated cancer cell 
apoptosis does not simply eliminate cancer cells but may enhance dissemination of 
some types of cancer (Itoh et al., 2017). Thus, induced apoptosis of carcinoma cells 
by CAF-EVs may also contribute to the increased OSCC aggressiveness and tumor 
dissemination. 
Either individually or pooled, CAF-EVs induced OSCC cells migration 
towards a wounded area and invasion into a gelatinous matrix. The stronger invasion 
effect was seen in the most aggressive cell lines, and HSC-3 cells invaded nearly 100 
times more than the controls without vesicles. In this case, the CAF-EVs may work by 
boosting an innate characteristic of the cancer cell. Similarly, Leca et al (2016) 
observed an increased migration of pancreatic ductal adenocarcinoma cells after the 
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uptake of CAF-derived ANXA6+ EVs, and Luga et al (2012) showed that CAFs 
exosomes stimulate breast cancer cells migration and metastasis in a CD81-
dependent manner.  
In addition to a solid gelatinous matrix, the invasion phenotype was also 
tested into a solid 3D human leiomyoma tissue and the HSC-3 cells treated with CAF-
EVs showed to invade a deeper and broader area, with more and smaller budding 
islands. Tumour budding is defined as the presence of single cancer cell or clusters of 
less than five cancer cells at the invasive front (Almangush et al., 2016). It represents 
two main features of malignancy: loss of cell adhesion and active tumor invasion 
(Marangon et al., 2014; Leão et al., 2017). High-intensity tumor budding was 
significantly associated with lymph node metastasis, depth of invasion, and CAF-
abundant stroma in OSCC (Marangon et al., 2014; Angadi et al., 2015, Seki et al., 
2017). Tumor budding is also associated with a poor prognosis in oral tongue cancer 
(Almangush et al. 2014 and 2015). The budding formation is considered the first step 
in metastasis of a solid tumor. The buds seem to be involved in degradation of the 
peritumoral connective tissue, evasion of host response and invasion into lymphatic 
and blood vessels leading to local and distant metastasis (Angadi et al., 2015; Seki et 
al., 2017). Shimoda et al. (2014) suggested that CAFs promote tumor metastasis by 
activating  RhoA and  Notch signaling pathways in breast cancer cells through the 
transfer of  ADAM10-rich  exosomes. In hepatocellular carcinoma, CAF-EVs could 
promote cell proliferation and metastasis through the miR-320a-PBX3 pathway (Zhang 
et al., 2017). Since our results demonstrated a possible correlation between CAF-EVs 
and tumor cells spreading in a human matrix, it may represent the initial step for local 
invasion and metastasis.  
Protein cargo of CAF- and NOF-EVs has not been extensively or 
systematically addressed before. From our findings, 32 proteins were listed among the 
100 most frequently proteins found in exosomes 
(http://exocarta.org/exosome_markers_new), including ANXA, FLOT1, and HSPA8, 
commonly used as vesicles markers (Lötvall et al., 2014; Kowal et al., 2016). This is 
compatible with the GO annotation results that showed an enrichment of  80% for 
vesicle-related proteins (GO.0031982). Similarly to our findings on the differentially 
expressed proteins in CAF-EVs, Shimoda et al (2014) compared the protein content of 
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TIMPless with wild-type fibroblasts exosomes and found that the first was significantly 
enriched in extracellular matrix proteins. 
Bioinformatic tools were applied to uncover the interactomics of the listed 
proteins and genes. The top annotated KEGG pathways among HSC-3 EV-treated 
cells, Glycolysis/Gluconeogenesis and Starch and sucrose metabolism, are metabolic 
pathways involved in the progression of breast, colorectal and prostate cancers (Zhu 
et al., 2014;  Haukaas et al., 2016; Bi et al., 2006; Kaushik et al., 2016). Glycolysis 
metabolism is highly activated in malignant cells, and this phenomenon is called the 
Warburg effect. A high rate of glycolytic flux is a central metabolic hallmark of 
neoplastic tumors since glycolysis is used by cancer cells preferentially to satisfy their 
increased energetic and biosynthetic requirements (Zhu et al., 2014). The focal 
adhesion pathway, previously shown to be enriched for genes expressed by CAF cells 
from non-small cell lung carcinoma (Navab et al., 2011), was also enriched in our set 
of CAF-EVs treated cells. For mesenchymal and epithelial migration to occur, the actin-
rich protrusions, which contain several receptors for extracellular matrix (ECM) 
proteins, must bind to the substratum (Di Blasio et al., 2017). Focal adhesion 
complexes facilitating cell–ECM contact and connection between ECM and actin 
cytoskeleton play mechanistically the key role as they structurally and functionally 
control the cell's morphology and cytoplasmic signaling for survival, proliferation, 
differentiation, and motility (Eke and Cordes, 2015).  
As a summary, CAF-EVs promoted OSCC cells apoptosis, migration and 
budding pattern invasion into a human 3D organotypic matrix in vitro. Interatomic 
analysis of the protein cargo and gene expression of treated cells revealed the 
involvement of genes related to metabolic pathways and cytoskeleton organization, 
known to support cancer growth and progression. 
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Supplementary Material 
 
 
 
Supplementary Figure 1. Gene expression of different markers on CAF and NOF cell 
lines. Gene expression levels of SDF-1, HGF, FAP, TIMP1, TIMP2, TIMP3, and TIMP4 were 
accessed by qPCR. The bars represent the fold changes based on PPIA expression. No 
differences between CAF and NOF cells were noted in the gene expression of the analyzed 
genes. 
 
 
Supplementary Table 1. Primer sequences used for the RT-qPCR assays. 
Gene              Forward (5’-3’)          Reverse (5’-3’) 
PPIA GCTTTGGGTCCAGGAATGG GTTGTCCACAGTCAGCAATGGT 
α-SMA GCAGCCCAGCCAAGCACTGT TGGGAGCATCGTCCCCAGCA 
FAP CCCACATGACCCACTTCCTAA GGCTTGCATCTGCATCGTTT 
HGF TTGTCAGCGCTGGGATCA CGGGATATCTTTCAGGCAAGAA 
SDF-1 GATTGTAGCCCGGCTGAAGA TCCACTTTAGCTTCGGGTCAA 
TIMP1 GCACATCACTACCTGCAGTTTTG CCCGGCGCTGAGCTAAG 
TIMP2 GACAAGCAGACTGCGCATGT CCACGGACCGAGCGATT 
TIMP3 TTCCCTGCGGAGTCGATAAA CTCCTCACCAAGGCCTAACAGA 
TIMP4 TCAGGTCCTCAGTGATGGAAAAGT GTCCTCCCAGGGCTCGAT 
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Supplementary Table 2. Differentially expressed genes in HSC-3 cells treated with CAF- and NOF-EVs normalized by the control group 
(untreated HSC-3 cells). 
     
CAF-HSC3 
vs.Ctrl 
NOF-HSC3 
vs.Ctrl 
FC 
Probe set Description Accession 
Entrez 
Gene Gene   
 
204392_at calcium/calmodulin-dependent protein kinase I NM_003656 8536 CAMK1 -161,99 -124,53 1,301 
238959_at c-Mpl binding protein AI082828 113251 LARP4 -182,44 -141,27 1,291 
1552312_a_at microfibrillar-associated protein 3 NM_005927 4238 MFAP3 -124,88 -129,14 0,967 
232171_x_at kelch domain containing 4 AK001742 54758 KLHDC4 -158,96 -192,75 0,825 
214177_s_at pre-B-cell leukemia transcription factor interacting protein 1 AI935162 57326 PBXIP1 -165,34 -226,31 0,731 
210589_s_at 
glucosidase, beta; acid (includes glucosylceramidase) /// 
glucosidase, beta; acid, pseudogene D13287 2629 /// 2630 GBA -164,27 -287,34 
 
0,572 
222664_at potassium channel tetramerisation domain containing 15 AI808448 79047 KCTD15  -129,45 -186,13 0,695 
204106_at testis-specific kinase 1 NM_006285 7016 TESK1  -132,41 -204,66 0,647 
1564129_a_at 
Quinolinate phosphoribosyltransferase (nicotinate-
nucleotide pyrophosphorylase (carboxylating)) AK090801 23475 QPRT -177,17 -332,02 
 
0,534 
227404_s_at Early growth response 1 AI459194 1958 EGR1 290,54 183,73 1,581 
208624_s_at eukaryotic translation initiation factor 4 gamma, 1 BE966878 1981 EIF4G1 300,51 402,49 0,747 
217878_s_at cell division cycle 27 AI203880 996 CDC27 391,12 369,81 1,058 
205809_s_at Wiskott-Aldrich syndrome-like BE504979 8976 WASL 175,85 180,49 0,974 
225851_at farnesyltransferase, CAAX box, beta BF131248 2342 FNTB 127,97 198,88 0,643 
212720_at poly(A) polymerase alpha AI670847 10914 PAPOLA 143,03 155,41 0,920 
210544_s_at aldehyde dehydrogenase 3 family, member A2 BC002430 224 ALDH3A2 155,26 216,16 0,718 
1558093_s_at matrin 3 BI832461 9782 MATR3 111,74 136,14 0,821 
201615_x_at caldesmon 1 AI685060 800 CALD1 160,93 108,37 1,485 
201299_s_at MOB1, Mps One Binder kinase activator-like 1B (yeast) NM_018221 55233 MOBKL1B  346,92 409,58 0,847 
1557227_s_at translocated promoter region (to activated MET oncogene) AW235355 7175 TPR 125,08 140,87 0,888 
1558378_a_at chromosome 14 open reading frame 78 BC004283 113146 AHNAK2 432,57 449,08 0,963 
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233827_s_at suppressor of Ty 16 homolog (S. cerevisiae) AK024072 11198 SUPT16H 276,56 373,1 0,741 
201294_s_at WD repeat and SOCS box-containing 1 N24643 26118 WSB1 144,61 176,15 0,821 
228427_at F-box protein 16 BF196856 157574 FBXO16 140,92 -153,01 -0,921 
       
 
Only differentially expressed on CAF-HSC3 treated group      
 
244559_at Vacuolar protein sorting 52 (yeast) AI809719 6293 VPS52   
 
220867_s_at 
solute carrier family 24 (sodium/potassium/calcium 
exchanger), member 2 NM_020344 25769 SLC24A2   
 
209704_at 
Likely ortholog of mouse metal response element binding 
transcription factor 2 AL523380 22823 MTF2   
 
222387_s_at vacuolar protein sorting 35 (yeast) BG476669 55737 VPS35   
 
231850_x_at KIAA1712 AB051499 80817 CEP44   
 
212551_at CAP, adenylate cyclase-associated protein, 2 (yeast) NM_006366 10486 CAP2   
 
216242_x_at 
hypothetical protein MGC13098 /// DNA directed RNA 
polymerase II polypeptide J-related gene AW402635 
246721 /// 
84820 POLR2J2   
 
217312_s_at 
collagen, type VII, alpha 1 (epidermolysis bullosa, 
dystrophic, dominant and recessive) L23982 1294 COL7A1   
 
202275_at glucose-6-phosphate dehydrogenase NM_000402 2539 G6PD   
 
202411_at interferon, alpha-inducible protein 27 NM_005532 3429 IFI27   
 
232520_s_at NSFL1 (p97) cofactor (p47) AK023585 55968 NSFL1C   
 
208907_s_at mitochondrial ribosomal protein S18B BC005373 28973 MRPS18B   
 
211716_x_at 
Rho GDP dissociation inhibitor (GDI) alpha /// Rho GDP 
dissociation inhibitor (GDI) alpha BC005851 396 ARHGDIA   
 
211799_x_at Major histocompatibility complex, class I, C U62824 3107 HLA-C   
 
49485_at PR domain containing 4 W22625 11108 PRDM4   
 
202151_s_at ubiquitin associated domain containing 1 NM_016172 10422 UBAC1   
 
206138_s_at phosphatidylinositol 4-kinase, catalytic, beta polypeptide NM_002651 5298 PI4KB   
 
209800_at 
keratin 16 (focal non-epidermolytic palmoplantar 
keratoderma) AF061812 3868 KRT16   
 
218777_at chromosome 8 open reading frame 20 NM_025232 80346 REEP4   
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202387_at 
BCL2-associated athanogene /// BCL2-associated 
athanogene NM_004323 573 BAG1   
 
209929_s_at 
inhibitor of kappa light polypeptide gene enhancer in B-cells, 
kinase gamma AF091453 8517 IKBKG   
 
221423_s_at 
golgi membrane protein SB140 /// golgi membrane protein 
SB140 NM_030799 81555 YIPF5   
 
201841_s_at heat shock 27kDa protein 1 NM_001540 3315 HSPB1   
 
208523_x_at histone 1, H2bi NM_003525 8346 HIST1H2BC   
 
207396_s_at 
asparagine-linked glycosylation 3 homolog (yeast, alpha-
1,3-mannosyltransferase) NM_005787 10195 ALG3   
 
202587_s_at adenylate kinase 1 BC001116 203 AK1   
 
200766_at cathepsin D (lysosomal aspartyl protease) NM_001909 1509 CTSD   
 
202996_at polymerase (DNA-directed), delta 4 NM_021173 57804 POLD4   
 
201062_at stomatin M81635 2040 STOM   
 
223694_at tripartite motif-containing 7 AF220032 81786 TRIM7   
 
228519_x_at cold inducible RNA binding protein AW027567 1153 CIRBP   
 
223300_s_at hypothetical protein FLJ23518 AI286012 79780 CCDC82   
 
217977_at selenoprotein X, 1 NM_016332 51734 MSRB1   
 
216521_s_at chromosome X open reading frame 53 S72931 79184 BRCC3   
 
239012_at IBR domain containing 2 R83905 255488 RNF144B   
 
244804_at Sequestosome 1 AW293441 8878 SQSTM1   
 
218619_s_at suppressor of variegation 3-9 homolog 1 (Drosophila) NM_003173 6839 SUV39H1   
 
231616_at Glycophorin A (includes MN blood group) T72620 2993 GYPA   
 
       
 
Only differentially expressed on NOF-HSC3 treated group      
 
222025_s_at 5-oxoprolinase (ATP-hydrolysing) AI991887 26873 OPLAH   
 
221602_s_at 
Fas apoptotic inhibitory molecule /// Fas apoptotic inhibitory 
molecule AF057557 9214 FCMR   
 
238883_at Thyroid hormone receptor-associated protein 2 AW975051 23389 THRAP3   
 
213218_at zinc finger protein 187 AV705032 7741 ZSCAN26   
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200808_s_at zyxin NM_003461 7791 ZYX   
 
200672_x_at spectrin, beta, non-erythrocytic 1 NM_003128 6711 SPTBN1   
 
210864_x_at hemochromatosis AF144240 3077 HFE   
 
219222_at ribokinase NM_022128 64080 RBKS   
 
219640_at claudin 15 NM_014343 24146 CLDN15   
 
222537_s_at CDC42 small effector 1 W44413 56882 CDC42SE1   
 
226324_s_at selective LIM binding factor, rat homolog AB033005 26160 IFT172   
 
231861_at low density lipoprotein receptor-related protein 10 AK025898 26020 LRP10   
 
224079_at interleukin 17C AF152099 27189 IL17C   
 
230055_at chromosome 6 open reading frame 148 AL037414 80759 C6orf148   
 
203014_x_at RUN and TBC1 domain containing 3 NM_015705 27352 RUTBC3   
 
229303_at Splicing factor 3b, subunit 1, 155kDa AI018793 23451 SF3B1   
 
1554444_s_at chromosome 2 open reading frame 18 BC028081 54978 SLC35F6   
 
1553096_s_at BCL2-like 11 (apoptosis facilitator) NM_138627 10018 BCL2L11   
 
241640_at B-cell receptor-associated protein 29 BG149769 55973 BCAP29   
 
216222_s_at myosin X AI561354 4651 MYO10   
 
222521_x_at 
NADH dehydrogenase (ubiquinone) 1, subcomplex 
unknown, 2, 14.5kDa AL040789 4718 NDUFC2   
 
40359_at chromosome 11 open reading frame 13 M91083 8045 RASSF7   
 
219123_at zinc finger protein 232 NM_014519 7775 ZNF232   
 
202048_s_at chromobox homolog 6 NM_014292 23466 CBX6   
 
218753_at hypothetical protein FLJ10307 NM_018053 55113 XKR8   
 
204078_at synaptonemal complex protein SC65 NM_006455 10609 P3H4   
 
202510_s_at tumor necrosis factor, alpha-induced protein 2 NM_006291 7127 TNFAIP2   
 
203837_at mitogen-activated protein kinase kinase kinase 5 NM_005923 4217 MAP3K5   
 
209057_x_at CDC5 cell division cycle 5-like (S. pombe) AB007892 988 CDC5L   
 
211504_x_at Rho-associated, coiled-coil containing protein kinase 2 D87931 9475 ROCK2   
 
214955_at transmembrane protease, serine 6 AI912086 164656 TMPRSS6   
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204300_at PET112-like (yeast) NM_004564 5188 GATB   
 
213746_s_at filamin A, alpha (actin binding protein 280) AW051856 2316 FLNA   
 
218511_s_at pyridoxine 5'-phosphate oxidase NM_018129 55163 PNPO   
 
223662_x_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 59 AL136611 83479 DDX59   
 
211074_at folate receptor 1 (adult) /// folate receptor 1 (adult) AF000381 2348 FOLR1   
 
201072_s_at 
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily c, member 1 AW152160 6599 SMARCC1   
 
212198_s_at transmembrane 9 superfamily protein member 4 AL515964 9777 TM9SF4   
 
200923_at lectin, galactoside-binding, soluble, 3 binding protein NM_005567 3959 LGALS3BP   
 
211793_s_at abl interactor 2 AF260261 10152 ABI2   
 
233779_x_at Serine/threonine kinase 3 (STE20 homolog, yeast) AK022046 6788 STK3   
 
203073_at component of oligomeric golgi complex 2 NM_007357 22796 COG2   
 
211464_x_at caspase 6, apoptosis-related cysteine protease U20537 839 CASP6   
 
202013_s_at exostoses (multiple) 2 NM_000401 2132 EXT2   
 
212218_s_at fatty acid synthase AI954041 2194 FASN   
 
210042_s_at cathepsin Z AF073890 1522 CTSZ   
 
217840_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 41 NM_016222 51428 DDX41   
 
221806_s_at hypothetical protein FLJ10707 BF590997 55209 SETD5   
 
225093_at utrophin (homologous to dystrophin) N66570 7402 UTRN   
 
226916_x_at dipeptidylpeptidase 9 AW190431 91039 DPP9   
 
216036_x_at WD and tetratricopeptide repeats 1 AK001734 23038 WDTC1   
 
221853_s_at 
NODAL modulator 1 /// NODAL modulator 2 /// NODAL 
modulator 3 N39536 
23420 /// 
283820 /// 
408050 NOMO   
 
236022_at Myosin head domain containing 1 AI650341 80179 MYO19   
 
202756_s_at glypican 1 NM_002081 2817 GPC1   
 
216450_x_at tumor rejection antigen (gp96) 1 AK025862 7184 HSP90B1   
 
207305_s_at KIAA1012 NM_014939 22878 TRAPPC8   
 
221123_x_at zinc finger protein 395 NM_018660 55893 ANF395   
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231825_x_at activating transcription factor 7 interacting protein AK025060 55729 ATF7IP   
 
232120_at 
Epidermal growth factor receptor (erythroblastic leukemia 
viral (v-erb-b) oncogene homolog, avian) AA678124 1956 EGFR   
 
204978_at 
splicing factor, arginine/serine-rich 16 (suppressor-of-white-
apricot homolog, Drosophila) NM_007056 11129 CLASRP   
 
214626_s_at glucosidase, alpha; neutral AB AK026548 23193 GANAB   
 
208916_at 
solute carrier family 1 (neutral amino acid transporter), 
member 5 AF105230 6510 SLC1A5   
 
207365_x_at ubiquitin specific protease 34 NM_014709 9736 USP34   
 
241919_x_at WD repeat domain 31 BE870625 114987 WDR31   
 
201633_s_at outer mitochondrial membrane cytochrome b5 AW235051 80777 CYB5B   
 
213716_s_at secreted and transmembrane 1 BF939675 6398 SECTM1   
 
218871_x_at chondroitin sulfate GalNAcT-2 NM_018590 55454 CSGALNACT2  
 
37152_at peroxisome proliferative activated receptor, delta L07592 5467 PPARD   
 
204314_s_at cAMP responsive element binding protein 1 NM_004379 1385 CREB1   
 
209344_at tropomyosin 4 BC002827 7171 TPM4   
 
201625_s_at insulin induced gene 1 BE300521 3638 INSIG1   
 
214594_x_at ATPase, Class I, type 8B, member 1 BG252666 5205 ATP8B1   
 
203057_s_at PR domain containing 2, with ZNF domain AV724783 7799 PRDM2   
 
208621_s_at villin 2 (ezrin) BF663141 7430 EZR   
 
219231_at nuclear receptor coactivator 6 interacting protein NM_024831 96764 TGS1   
 
206562_s_at casein kinase 1, alpha 1 NM_001892 1452 CSNK1A1   
 
202323_s_at acyl-Coenzyme A binding domain containing 3 AI636775 64746 ACBD3   
 
33148_at zinc finger RNA binding protein AI459274 51663 ZFR   
 
226046_at mitogen-activated protein kinase 8 AU152505 5599 MAPK8   
 
211977_at G protein-coupled receptor 107 AK024651 57720 GPR107   
 
202137_s_at zinc finger, MYND domain containing 11 NM_006624 10771 ZMYND11   
 
FC: absolut fold changestaking CAF-EVs treatment as reference.
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Supplementary Table 3. Exclusively and differentially expressed proteins in 
CAF- and NOF-EVs.   
 Accession Number MW* p* FC* 
Exclusive proteins in CAF-EVs (11/141)   
Isoform 2 of Importin subunit beta-1  GN=KPNB1 IMB1_HUMAN 81  0.44  
Ig gamma-1 chain C region GN=IGHG1  A0A087WV47_HUMAN 51  0.44  
Pentraxin-related protein PTX3 GN=PTX3  PTX3_HUMAN 42  0.44  
Histidine-rich glycoprotein GN=HRG  HRG_HUMAN 60  0.44  
Calcium-binding protein 39-like (Fragment) 
GN=CAB39L  B7ZBJ5_HUMAN  21  0.44 
 
H/ACA ribonucleoprotein complex subunit 3 
GN=NOP10  H0YM60_HUMAN 4  0.44 
 
Polyadenylate-binding protein 4-like GN=PABPC4L  PAB4L_HUMAN 42  0.44  
Isoform 4 of Protein Dok-7 GN=DOK7 DOK7_HUMAN 28  0.44  
Uncharacterized protein C4orf50 GN=C4orf50  E9PNW5_HUMAN 83  0.44  
Isoform B of Coagulation factor VII GN=F7 FA7_HUMAN 49  0.44  
Phosphoglycerate mutase 1 GN=PGAM1  PGAM1_HUMAN 29  0.44  
     
Overexpressed proteins in CAF-EVs (16/141)   
Tubulin alpha-1C chain GN=TUBA1C F5H5D3_HUMAN  58  0.17 11 
Glyceraldehyde-3-phosphate dehydrogenase 
GN=GAPDH  
E7EUT5_HUMAN  28  0.23 6.7 
Immunoglobulin J chain (Fragment) GN=IGJ  D6RD17_HUMAN  18  0.23 5.3 
Actin. cytoplasmic 1 GN=ACTB  ACTB_HUMAN  42  0.21 4.9 
Inter-alpha-trypsin inhibitor heavy chain H2 
GN=ITIH2 
A0A087WTE1_HUMAN 107  0.24 4 
Isoform 2 of Thrombospondin-1 GN=THBS1 TSP1_HUMAN 120  0.36 3.6 
Isoform 3 of Inter-alpha-trypsin inhibitor heavy chain 
H1 GN=ITIH1 
ITIH1_HUMAN 69  0.21 3.3 
Complement C3 GN=C3  CO3_HUMAN 187  0.34 3 
Isoform 2 of Annexin A2 GN=ANXA2 ANXA2_HUMAN 40  0.35 2.7 
Interstitial collagenase GN=MMP1  MMP1_HUMAN 54  0.51 2.7 
L-lactate dehydrogenase (Fragment) GN=LDHB  A8MW50_HUMAN 25  0.54 2.7 
Clathrin heavy chain GN=CLTC  A0A087WVQ6_HUMAN 192  0.54 2.7 
Apolipoprotein A-I GN=APOA1  APOA1_HUMAN 31  0.54 2.7 
Apolipoprotein C-III GN=APOC3  APOC3_HUMAN 11  0.54 2.7 
Collagen alpha-1(VI) chain GN=COL6A1  A0A087X0S5_HUMAN 108  0.54 2.7 
Cathepsin B GN=CTSB  CATB_HUMAN 38  0.54 2 
     
Overexpressed proteins in NOF-EVs (8/141)     
Isoform 2 of Serum albumin GN=ALB ALBU_HUMAN 47  0.53 3.4 
Collagen alpha-1(I) chain GN=COL1A1  CO1A1_HUMAN 139  0.6 3 
Keratin. type I cytoskeletal 9 GN=KRT9  K1C9_HUMAN 62  0.31 2.8 
Alpha-amylase 1 GN=AMY1A  AMY1_HUMAN 58  0.63 2.6 
Cullin-3 GN=CUL3  A0A087WTG3_HUMAN 39  0.67 2.2 
Protein TRAJ56 (Fragment) GN=TRAJ56  A0A075B6Z2_HUMAN 2  0.54 2.2 
Isoform 3 of Alpha-1-antitrypsin GN=SERPINA1 A1AT_HUMAN 35  0.67 2.2 
Isoform 2 of Heat shock protein HSP 90-alpha 
GN=HSP90AA1 HS90A_HUMAN 98  0.54 2.2 
     
*MW= molecular weight in Kilodaltons; p= p-value from t-test with Benjamini-Hochberg correction 
test; FC= fold change ≥2 by category; GN= gene. 
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Abstract 
Oral squamous cell carcinoma (OSCC) is one of the most common 
cancers worldwide, exhibiting variable incidences around the world, often 
attributed to environmental differences. The survival rates for OSCC are low and 
the prognosis is unpredictable, even in early-stage tumors, making the 
identification of biomarkers of great importance. Rho-associated coiled-coil 
kinase 2 (ROCK2), an oncoprotein that acts as a prognostic marker in solid 
tumors such as colorectal, breast, pancreatic, gastric, bladder and renal cancers, 
was analyzed in this study to establish its prognostic significance for OSCC 
patients. The ROCK2 immunohistochemical analysis was applied in samples 
from 93 OSCC from 2 centers in Brazil and Finland. The samples were also 
stained for isoform α of smooth muscle actin (α-SMA) to characterize the 
presence of cancer-associated fibroblasts (CAF) in the tumor stroma. 
Clinicopathological associations were analyzed using chi-square test, survival 
curves were constructed according to the Kaplan-Meier method, and Cox 
proportional hazard model was applied for multivariate survival analysis. 
Advanced clinical stage (p=0.002) and increased density of CAF (p=0.002) were 
significantly associated with high ROCK2 expression. The high expression of 
ROCK2 was also associated with shortened disease-specific survival (HR: 2.22, 
95% CI: 1.15-4.38, p=0.04), but the association did not remain after the Cox 
multivariate survival analysis. The findings suggest that high ROCK2 expression 
in OSCC may be important for tumor progression, but it is not an independent 
prognostic factor. 
 
Keywords: ROCK2, prognosis, oral squamous cell carcinoma, cancer-
associated fibroblasts. 
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Introduction 
Oral squamous cell carcinoma (OSCC), one of the 10 most prevalent 
cancers worldwide, has a global annual incidence of approximately 300,000 new 
cases and 145,000 deaths, with considerable geographic and environmental risk 
factor differences (Ferlay et al., 2015). Although the overall incidence of OSCC 
has been decreasing in some areas of the world, which is consistent with 
decreases in tobacco use, the global incidence of oral cavity cancers is predicted 
to rise in the next 20 years because of demographic changes (Shield et al., 2017). 
Clinical features including tumor size and cervical lymph node metastasis are the 
most consistent prognostic factors for OSCC, but it frequently shows 
unpredictable prognosis. Among the histological characteristics, depth of 
invasion has shown prognostic importance for OSCC (Almangush et al., 2015), 
leading to its incorporation in the T stage classification in the new edition of the 
stating manual of the American Joint Cancer Committee (Ridge et al, 2017). 
However, OSCC still shows significant morbidity and mortality rates, which have 
remained unchanged over recent decades (Warnakulasuriya, 2010). Therefore, 
better prognostic markers are required. 
Rho-associated coiled-coil kinase 2 (ROCK2) is an oncoprotein with 
important roles in tumor proliferation, apoptosis, adhesion, migration and 
invasion, and overexpression has been reported in tumor cells from 
hepatocellular carcinomas (Wong et al., 2015), pancreatic adenocarcinomas 
(Rath et al., 2017), colorectal cancers (Qiu et al., 2015), gastric cancers (Li et al., 
2016), breast carcinomas (Hsu et al., 2015), esophageal cancers (Wang et al., 
2016), renal cell carcinomas (Xu et al., 2016) and oral cancers (Jiang et al., 
2010). In most of those studies, overexpression has been related to tumor 
progression, metastasis and poor clinical outcome (Hsu et al., 2015; Li et al., 
2016; Qiu et al., 2015; Rath et al., 2017; Wang et al., 2016; Xu et al., 2016). 
ROCK2 expression is also observed in the tumor microenvironmental cells, 
including inflammatory cells, endothelial cells and cancer-associated fibroblasts 
(CAF) (Bozóky et al., 2013; Chen et al., 2014; Mali et al., 2014). In CAF, 
expression of ROCK2 is predicted to stimulate Rho kinase signaling pathway, 
which in turn may contribute to tumor cell survival, proliferation and tumor 
progression (Bozóky et al., 2013). In a recent meta-analysis, we pooled 1,328 
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OSCC cases from 12 studies and showed that abundance of CAF is correlated 
with clinicopathological features that reflect aggressiveness and dissemination of 
the disease and, more important, is associated with worse prognosis (Dourado 
et al, 2017). Owing to this pivotal function in cancer, ROCK2 has been suggested 
as a promising therapeutic target, but there is no data on the prognostic value for 
OSCC. On this context, we have evaluated the prognostic role of ROCK2 
expression in a cohort with 93 OSCCs from Brazil and Finland. 
 
Materials and Methods 
This study was carried out following the REMARK guidelines for tumor 
marker prognostic studies (McShane et al., 2005). 
 
Patients 
This study included samples from 93 patients with OSCC, who 
underwent radical surgery at the UOPECCAN Cancer Hospital (n=66), Cascavel, 
Brazil from 1998 to 2008, and at the University Hospital of Oulu, Finland (n=27) 
between 1979 and 2009. None of the patients received any prior therapy before 
surgery. Complete demographic and clinical data were collected from patient’s 
records and included gender, age, habits such as smoking and alcohol 
consumption, tumor stage, tumor site, type of treatment, histological grade, the 
status of the surgical margins, recurrence and survival. Tumor staging was 
performed according to the International Union Against Cancer (UICC) 2002 
staging system. The outcomes were categorized as disease-specific survival 
(DSS), time from treatment initiation until death due to cancer or last known date 
alive, and disease-free survival (DFS), time from treatment initiation until 
diagnosis of the first recurrence (local, regional or distant) or last follow-up 
information for those without recurrence. For DFS analysis, only survivors with 
follow-up information of at least 5 years were included. The study was approved 
by the ethics review board of each of the hospitals affiliated with the collaborative 
study. 
 
Tissue samples 
Paraffin-embedded blocks of all cases were retrieved and new 
sections were stained with hematoxylin and eosin. Tumors were graded 
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according to the 2017 World Health Organization classification. Surgical margin, 
identified as the closest distance between the tumor and the surgical resection 
edge was categorized into 2 groups based on the cut-off value of 5 mm. Margins 
of less than 5 mm were considered involved, and margins of 5 mm or more were 
classified as free. 
 
Immunohistochemistry 
Immunohistochemistry was performed on 3 µm sections. Slides were 
dewaxed in xylene and rehydrated by using a graded alcohol series. Endogenous 
peroxidase activity was blocked with a 3% hydrogen peroxide solution, and 
antigen retrieval was performed with 10 mM citric acid pH 6.0 in a pressure 
cooker. Slides were then incubated with primary antibodies against ROCK2 
(1:400, Abcam, USA) and isoform α of smooth muscle actin (α-SMA, 1:400, clone 
1A4, Dako, USA) at 4°C overnight, followed by biotinylated second antibodies, 
avidin-biotin complex and incubation with 3,3'-diaminobenzidine 
tetrahydrochloride (Dako, USA). Control reactions were performed by omission 
of the primary antibody. 
ROCK2 expression was assessed by two pathologists who were not 
aware of any clinical data. Scores were assigned according to the percentage of 
positive tumor cells and the intensity of the staining (Hsu et al., 2015; Wang et 
al., 2016). For the percentage of positive tumor cells, the scores were: 0, 
negative; 1, <25%; 2, 26%-50%; and 3, >51%. For intensity, the scores were: 0, 
negative; 1, weak; 2, moderate; and 3, strong. Final scores were calculated as 
the sum of the percentage of positive cells and the intensity of the staining, and 
for statistical analysis, samples were categorized into two groups. Low 
expression was defined as a final score <4 points (negative and low expression) 
and high expression (moderate and strong) was defined as a final score ≥4. CAF 
score was assessed as described by Kellermann et al. (2007). 
 
Statistical analysis 
Associations between immunohistochemical expression of ROCK2 
and clinicopathological parameters of the tumors were performed using cross-
tabulation and chi-square test. Survival curves were constructed based on the 
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Kaplan-Meier method and compared with the log-rank test. For multivariate 
survival analysis, the Cox proportional hazard model with a stepwise method was 
employed. The level of significance considered was 5% (p≤0.05). 
 
Results 
Out of 93 patients, 70 (75.2%) were men, and the age of the patients 
ranged from 32 to 86 years, with a median of 60 years. Most of the patients 
reported smoking (84.2%) and drinking alcohol (73.1%). Regarding clinical stage, 
37 (39.8%) patients were classified in early-stage (stages I and II) and 56 (60.2%) 
in advanced-stage (stages III and IV). The tongue was the most commonly 
affected site (58.7%) and other affected sites included the floor of mouth (29.3%), 
retromolar area (5.4%), palate (4.4%) and gingiva (2.2.%). Surgery as 
monotherapy was performed in 37 (40.2%) patients, whereas 47 (51.1%) were 
treated with a combination of surgery and postoperative radiotherapy and 8 
(8.7%) received surgery and postoperative radio-chemotherapy. Only 4 cases 
had surgical margins with less than 5 mm. The WHO grading system classified 
65 (69.9%) tumors as well differentiated, 18 (19.3%) as moderately differentiated 
and 10 (10.8%) as poorly differentiated. During follow-up, 34 patients developed 
recurrence. The overall survival ranged from 1 to 251 months, with a mean of 123 
months. Forty-three patients died due to the tumor. The clinicopathological 
features of patients are depicted in Supplementary Table 1. 
Eleven (11.8%) cases were negative for ROCK2. The expression of 
ROCK2 was localized in both nucleus and cytoplasm of the tumor cells, with 
variable distribution and intensity, with immunopositivity also found in some 
inflammatory cells and CAFs of the stroma (Fig. 1). Regarding the cytoplasmatic 
ROCK2 immunoreactivity, 24 (25.8%) samples were classified as low expression 
and 69 (74.2%) as high expression. 
High expression of ROCK2 was significantly associated with male 
gender (p=0.006), drinking habit (p=0.01), high clinical stage (0.002) and 
abundant CAF density in the stroma (p=0.002) (Table 1). No significant 
differences were found between ROCK2 expression and smoking habit, tumor 
site, treatment, histological grade, margin status and recurrence (Table 1). 
Univariate survival analysis based on log-rank test revealed a significant 
association of age, clinical stage of the tumor, CAF density and ROCK2 
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expression with DSS, and of age and CAF density with DFS (Table 2). Patients 
with high expression of ROCK2 had shorter DSS compared with patients with low 
ROCK2 expression (Fig. 2). High ROCK2 expression was associated with a 5-
year DSS of 42.9% compared with 70.3% for patients with low ROCK2 
immunoreactivity (p=0.04). Multivariate Cox proportional hazard regression 
model analysis was built to further evaluate the impact of ROCK2 expression on 
DSS and DFS (Table 3). In this analysis, ROCK2 did not remain as an 
independent prognostic factor, but age and clinical stage remained as 
independent prognostic factors for DSS, whereas age and CAF density were 
pointed out as prognostic factors of DFS in this cohort. 
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Figure 1. ROCK2 and α-SMA immunohistochemical staining in OSCC samples. Representative samples classified 
as negative (A) and positive (B) for ROCK2 immunostaining. (C) High power view revealing that tumor cells showed 
nucleous and cytoplasmatic positivity for ROCK2. Representative samples classified as (D) negative, (E) scanty, and 
(F) abundant for α-SMA immunostaining, indicating the absence of presence of CAF within the stroma. It should be 
highlighted that smooth muscle cells in the blood vessels can show positivity for α-SMA, as shown in Fig. D. (Original 
magnification: C x400; all the other images are x100).
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Table 1. Association between the clinicopathological parameters of the oral squamous cell 
carcinomas and the immunohistochemical expression of ROCK2. 
Parameter ROCK2 p value 
 Low expression 
No. of patients (%) 
High expression 
No. of patients (%) 
 
Age    
<58 years 9 (37.5) 35 (50.7)  
≥58 years 15 (62.5) 34 (49.3) 0.26 
Gender    
Male 13 (54.2) 57 (82.6)  
Female 11 (45.8) 12 (17.4) 0.006 
Smoking habit    
No 3 (30) 6 (12.8)  
Yes 7 (70) 41 (87.2) 0.18 
Drinking habit    
No 5 (62.5) 9 (20.5)  
Yes 3 (37.5) 35 (79.5) 0.01 
Clinical stage    
I/II 16 (66.7) 21 (30.4)  
III/IV 8 (58.4) 48 (69.6) 0.002 
Tumor site    
Tongue 10 (41.6) 35 (50.7)  
Others 14 (58.4) 34 (49.3) 0.44 
Treatment    
Surgery 12 (52.2) 25 (36.2)  
Surgery + RTX 11 (47.8) 36 (52.2)  
Surgery + RTX + CTX 0 8 (11.6) 0.15 
Histological grade    
WD/MD 13 (54.2) 52 (75.4)  
PD 11 (45.8) 17 (24.6) 0.06 
Margin status    
> 5 mm 22 (91.7) 67 (97.1)  
< 5 mm 2 (8.3) 2 (2.9) 0.26 
Recurrence    
No 16 (66.7) 43 (62.3)  
Yes 8 (33.3) 26 (37.7) 0.70 
CAF density    
Negative/Scanty 15 (62.5) 19 (27.5)  
Abundant 9 (37.5) 50 (72.5) 0.002 
RTX: radiotherapy, CTX: chemotherapy, WD: well-differentiated; MD: moderately-
differentiated; PD: poorly-differentiated; CAF: carcinoma-associated fibroblasts. 
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Table 2. Univariate analysis for disease-specific survival and disease-free survival of the oral 
squamous cell carcinoma patients. 
 Disease-Specific Survival Disease-Free Survival 
Parameter % in 5 
years 
HR (95% CI) / p 
value 
% in 5 
years 
HR (95% CI) / p 
value 
Age     
<58 years 56.9 Reference 71.6 Reference 
≥58 years 37.4 2.03 (1.11-3.71) / 
0.02 
44.9 2.84 (1.47-5.47) / 
0.003 
Gender     
Male 46.8 Reference 61.4 Reference 
Female 58.5 0.60 (0.30-1.21) / 
0.21 
54.3 1.27 (0.58-2.76) / 
0.50 
Smoking habit     
No 59.3 Reference 65.2 Reference 
Yes 43.6 1.35 (0.46-3.93) / 
0.52 
43.8 1.63 (0.76-15.22) / 
0.09 
Drinking habit     
No 56.3 Reference 67.1 Reference 
Yes 36.9 2.00 (0.90-4.45) / 
0.14 
59.7 1.01 (0.36-2.82) / 
0.98 
Clinical stage     
I/II 61.3 Reference 62.0 Reference 
III/IV 37.4 2.25 (1.23-4.10) / 
0.008 
58.9 1.05 (0.54-2.02) / 
0.88 
Tumor site     
Tongue 55.7 Reference 56.5 Reference 
Others 42.8 1.45 (0.79-2.65) / 
0.21 
62.9 0.75 (0.39-1.45) / 
0.41 
Treatment     
Surgery 61.7 Reference 61.2 Reference 
Surgery + RTX 44.5 1.62 (0.86-3.04) / 
0.13 
55.8 1.03 (0.51-2.05) / 
0.93 
Surgery + RTX + CTX 50.0 1.23 (0.38-4.27) / 
0.64 
62.5 0.83 (0.25-2.66) / 
0.75 
Histological grade     
WD/MD 43.8 Reference 57.5 Reference 
PD 67.3 0.56 (0.29-1.09) / 
0.13 
63.4 0.93 (0.45-1.91) / 
0.84 
Margin status     
> 5 mm 49.1 Reference 58.8 Reference 
< 5 mm 50.0 0.83 (0.17-3.89) / 
0.79 
66.7 0.63 (0.13-3.19) / 
0.65 
Country     
Finland 72.0 Reference 57.0 Reference 
Brazil 57.7 2.00 (1.03-3.90) / 
0.08 
60.0 0.78 (0.37-1.61) / 
0.47 
CAF density     
Negative/Scanty  64.4 Reference 70.4 Reference 
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Abundant 41.5 2.14 (1.16-3.94) / 
0.02 
51.6 1.85 (1.19-3.09) / 
0.03 
ROCK2     
Low 70.3 Reference 64.9 Reference 
High 42.9 2.22 (1.15-4.38) / 
0.04 
56.6 1.27 (0.71-2.25) / 
0.35 
RTX: radiotherapy, CTX: chemotherapy, WD: well-differentiated; MD: moderately-
differentiated; PD: poorly-differentiated; CAF: carcinoma-associated fibroblasts. 
 
 
 
Table 3. Cox multivariate analysis for the risk of death. 
Parameter Disease-Specific Survival Disease-Free Survival 
 HR (95% CI) p value HR (95% CI) p value 
Age     
≤58 years Reference  Reference  
>58 years 2.44 (1.30-4.56) 0.005 2.98 (1.46-6.08) 0.003 
Clinical stage     
I/II Reference    
III/IV 2.49 (1.32-4.70) 0.004   
CAF density     
Negative/Scanty   Reference  
Abundant   2.08 (1.27-7.43) 0.01 
CAF: carcinoma-associated fibroblasts. 
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Figure 2. Kaplan-Meier curves representing the cumulative 5-year survival of the OSCC 
patients. Univariate analysis showed an association between ROCK2 expression and DSS (A, 
p=0.04), following the same trend for DFS but losing significance (B, p=0.35). The same 
analysis revealed an association of CAF density with DSS (C, p=0.02) and DFS (D, p=0.03). 
 
 
Discussion 
Alterations in the expression level of ROCK2 have been reported in several 
cancers, and the overexpression was an indicator of worse prognosis (Hsu et al., 2015; 
Li et al., 2016; Qiu et al., 2015; Rath et al., 2017; Xu et al., 2016). One early 
investigation showed that increased ROCK2 expression controls migration and 
invasion of OSCC cells in vitro (Jiang et al., 2010), but the prognostic value of ROCK2 
has never been verified in oral cancers. We found in the current study that high ROCK2 
expression is associated with the advanced clinical stage, which is well-known 
affecting tumor aggressiveness. Furthermore, high ROCK2 expression was an 
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indicator of poor DSS, with those patients’ 5-year survival being 42.9% compared with 
70.3% for patients with low ROCK2 expression. For DFS, the result was similar (56.6% 
for high ROCK2 vs. 64.9% for low ROCK2), but not statistically significant. 
ROCK2 belongs to the serine-threonine kinase AGC family and is a 
downstream intracellular messenger following small GTPase RhoA activity (Julian and 
Olson, 2014). Since the description that ROCK2 controls cytoskeleton organization by 
regulating actin filaments (Amano et al., 1997), many studies have investigated its role 
in cancer, revealing the participation in a wide range of processes related to 
tumorigenesis in vitro such as proliferation, apoptosis, adhesion, migration, and 
invasion. In consonance, ROCK inhibition due to synthetic drugs/peptides or 
microRNAs were found to suppress tumor growth and metastasis using in vivo animal 
models (Patel et al., 2014; Qiu et al., 2015; Rath et al., 2017; Wong et al., 2015). In a 
recent study, Vennin et al. (2017) showed that priming with Fasudil, a specific ROCK 
inhibitor, disrupts the extracellular matrix scaffold, improving the treatment 
effectiveness in a mouse model of pancreatic cancer. Together, those results suggest 
that ROCK2 might be a molecular target for preventing cancer progression and 
metastasis. 
The increased ROCK2 expression has been reported in association with 
metastasis and shorter survival of cancer patients. For example, in pancreatic cancers, 
ROCK2 levels rose with increasing tumor stage (advanced tumors showed significantly 
higher levels than early stage and even normal pancreatic tissue) and the survival of 
patients with genomic amplification or significantly elevated mRNA was significantly 
shorter than in patients without ROCK2 alterations (Rath et al., 2017). Based only on 
univariate Kaplan-Meier analysis, patients with colorectal cancers and high ROCK2 
expression had significantly shorter survival rates than patients whose tumors showed 
low ROCK2 expression (Qiu et al., 2015). Our results are in line with those previous 
ones regarding associations with advanced clinical stage of tumors and shortened 
survival. Furthermore, the only published study evaluating ROCK2 in oral cancer 
demonstrated that in highly metastatic oral tongue SCC cells, enhanced expression of 
ROCK2, due to a reduction in miR-138 levels, increases the activity of Rho GTPase 
signaling cascade, which promotes cell migration and invasion (Jiang et al., 2010). 
Thus, little has been uncovered regarding the biological mechanisms related to 
ROCK2 in oral cancer, but our results preliminarily reveal an association with clinical 
outcome. 
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Another interesting finding of the present study relies on the CAF analysis. 
We recently performed a systematic review and meta-analysis to verify the value of 
CAF in OSCC, and demonstrated that high presence of CAF is frequently associated 
with parameters that worsen the prognosis, including advanced disease stage, 
recurrence, tumor grade, depth of invasion, vascular, lymphatic and neural invasion 
and extranodal metastatic spread, and most important, high presence of CAF 
significantly predicted shortened time to disease-relapse and an overall decrease in 
survival (Dourado et al., 2017). The pro-tumorigenic effects of CAF are related to the 
vast repertoire of secreted molecules, which can directly influence the behavior of 
cancer cells, stimulating proliferation, invasion, and metastasis. Among the well-known 
molecules are stromal derived factor 1 (SDF-1/CXCL12) (Ishii et al., 2016), activin A 
and matrix metalloproteases (Sobral et al., 2011), some types of collagen and other 
extracellular matrix proteins such as fibronectin (Bagordakis et al., 2016), and ROCK2 
(Bozóky et al., 2013). Our findings in this study revealed ROCK2 positivity in both tumor 
and stroma cells, but the intensity was lower in stroma cells compared to tumor cells. 
A significant association between ROCK2 expression by tumor cells and the density of 
CAF was observed. Rath and collaborators (2017) demonstrated that ROCK activation 
led to significant collagen degradation and remodeling associated with increased 
invasive growth, and the treatment of ROCK‐activated invasive cells with GM6001, a 
matrix metalloprotease inhibitor, blocks those processes. The significant association 
of ROCK2 and CAF suggests the organization of a more invasion-permissive 
microenvironment, facilitating tumor progression and metastasis. 
Most of the characteristics of patients in the current study were similar to 
those described in previous studies. With no apparent explanation, ROCK2 expression 
was significantly more common in males and drinkers. Similarly, Liu et al. (2015) found 
a significantly higher ROCK2 expression in esophageal squamous cell carcinomas in 
Chineses with Kazakh ancestry that in patients with Han Chinese origin. Interestingly, 
besides the predictable associations of the clinical stage with DSS and CAF density 
with DFS, we also found a significant association of age with DSS and DFS in both 
univariate and multivariate analysis. Those results are in line with previous studies that 
showed a worse survival in elderly patients with OSCC than in young patients (Chang 
et al., 2013; Goldenberg et al., 2009; Ho et al., 2008; Oliveira et al., 2008; Pontes et 
al., 2011). An important feature in favor of a causal effect of advanced age on survival 
is that previous studies have reported frequent comorbidities in the cardiovascular, 
gastrointestinal and respiratory systems in elderly people, and demonstrated a 
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significant impact on the prognosis of oral cancer patients (Ho et al., 2008; Sawazaki-
Calone et al., 2015). Thus, those results suggest that age may affect the survival of 
oral cancer patients due to the comorbid illnesses. 
In closing, the expression of ROCK2 in OSCC is associated with advanced 
clinical stage of the tumor and poor survival, which indicates that ROCK2 may be 
involved in OSCC progression. Although ROCK2 may not be an independent 
prognostic factor, it should be further verified by prospective studies and more 
comprehensive follow-up. 
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Supplementary Material 
 
Supplementary Table 1. Summary of the clinicopathological characteristics of the patients with 
oral squamous cell carcinoma from this cohort. 
Characteristics No. of patients % 
Age (years)   
Mean ± SD 60 ± 12.5  
Median 58  
Gender   
Male 70 75.2 
Female 23 24.8 
Smoking habit   
No 9 15.8 
Yes 48 84.2 
Drinking habit   
No 14 26.9 
Yes 38 73.1 
Clinical stage   
I/II 37 39.8 
III/IV 56 60.2 
Tumor site   
Tongue 54 58.7 
Floor of mouth 27 29.3 
Retromolar area 5 5.4 
Palate 4 4.4 
Gingiva 2 2.2 
Treatment   
Surgery 37 40.2 
Surgery + Radiotherapy 47 51.1 
Surgery + Radiotherapy + Chemotherapy 8 8.7 
Histological grade   
Well-differentiated 65 69.9 
Moderately-differentiated 18 19.3 
Poorly-differentiated 10 10.8 
Margin status   
> 5 mm 89 95.7 
< 5 mm 4 4.3 
Recurrence   
No 59 63.4 
Yes 34 36.6 
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3 DISCUSSION 
 
CAF are widely known as the major component of the TME in solid tumors 
and its relevance in tumor progression and metastasis has received more attention in 
the last years. Firstly, we showed through meta-analysis that high levels of CAF (α-
SMA positive fibroblasts detected by immunohistochemistry) in the TME of OSCC 
patients could predict shortened time to disease-free survival and an overall decrease 
in survival. Meta-analysis involves statistical methods to integrate findings from 
different studies, and can be used to answer a specific question by: combining data 
from individual studies that have insufficient sample size, to explore inconsistent 
results and possible sources of heterogeneity among studies or to identify gaps and 
problems in the published literature, providing researchers with important information 
that is needed to plan future research (Dawson et al., 2016). Due to its reliability, meta-
analysis has been used to access the value of prognostic and diagnostic markers in 
cancer of the head and neck region, including OSCC (Gao et al., 2003; Jamali et al., 
2015; Guerra et al., 2016; Marques et al., 2016; Almangush et al., 2017). The 
evaluation of some important prognostic biomarkers in OSCC at the time of diagnosis 
might allow the identification of a subset of patients who require more aggressive 
management. Therapeutic approaches such as the use of some molecular inhibitors 
directed against specific biomarkers, along with adjuvant radio- and/or chemotherapy, 
are promising treatments for OSCC patients (Oliveira and Ribeiro-Silva, 2011). 
The present study provides evidence that immunohistochemical detection 
of CAF (α-SMA-positive fibroblasts) is an independent marker of shortened disease-
free survival and poor overall survival in patients with OSCC, after pooling data from 
12 eligible studies comprising 1328 patients. Immunohistochemistry (IHC) is a globally 
available tool that complements histopathological analysis by detecting gene 
expression at the protein level. The main advantage of the identification of putative 
prognostic biomarkers in OSCC by IHC is the establishment of a direct association 
between the morphology and these biomarkers, which can aid in determining their 
functional relevance. IHC can be performed on formalin-fixed paraffin-embedded 
specimens that can be stored for a long time, thereby allowing retrospective studies of 
a large population (Oliveira and Ribeiro-Silva, 2011). 
Our study also highlighted the fact that CAF was frequently reported in 
association with parameters that worsen the prognosis in OSCC, including advanced 
disease stage (TNM classification), recurrence, tumor grade, depth of invasion, 
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vascular, lymphatic and neural invasion and extranodal metastatic spread. Altogether, 
the results confirm that immunodetection of CAFs in the stroma of OSCC can predict 
a worse prognosis and can help in the better management of these patients. Given its 
easy applicability and benefits, we suggest the addition of CAF density as one of the 
OSCC outcome prediction tools in histopathology services. The limitations of this study 
rely on the lack of standardization in the methods used to quantify CAF and the 
differences in the reported clinicopathological features. From our point of view, the 
limitations did not compromise the evidence, but suggested the urgent need for 
adoption of guidelines such as the REMARK initiative (McShane et al., 2005), when 
evaluating the value of prognostic markers. 
Patients with early stage OSCC (stage I or II) and non-nodal metastasis 
patients, who have been treated by surgery or radiotherapy, have excellent survival 
rate. However, two-thirds of OSCC are diagnosed at advanced stage (stage III or IV) 
(Ni et al., 2015). Interestingly, in our study, high CAF density was linked to advanced 
disease stage but not to early stage OSCC. When evaluating only early stage 
(T1/T2N0M0) tongue SCC, Almangush et al. (2014) observed that CAF is not a good 
prognostic factor and it is unusual to have a high density of these fibroblasts in the 
initial disease. CAF density is a time-dependent phenomenon in OSCC as CAF are 
believed to be recruited into the tumor from a variety of sources (Kalluri et al., 2016). 
In addition, CAF are also an infrequent finding in slower growing and less invasive 
growth pattern lesions, such as proliferative verrucous leukoplakia-associated 
squamous cell carcinoma (Akrish et al., 2017). Hence, the crosstalk within the TME is 
essential in the activation and recruitment of cells that will undergo transformation into 
CAF, what can explain the increase of CAF density following the tumor progression. 
The conventional histopathological grading of tumors is prone to subjective 
interpretation and intensive research on prognostic molecular markers in cancer 
reflects a general need for better prognostic tools (Soland and Brusevold, 2013). The 
clinical TNM (tumor, node, metastasis) classification of malignant tumors and the 
World Health Organization (WHO) histopathological grading system are inaccurate for 
the prediction of prognosis on an individual basis. Even patients presenting with a small 
tumor can experience recurrences, metastasis, and death (Soland and Brusevold, 
2013). Efforts have been made in the direction of a better prediction of the OSCC 
progression, like the incorporation of depth of invasion in the T stage classification by 
the American Joint Cancer Committee (Ridge et al, 2017), and the development of 
new grading systems such as the BD model, significantly associated with disease 
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outcome as an independent prognostic marker (Almangush et al., 2015; Sawazaki-
Calone et al., 2015). 
Additionally, we addressed by IHC the prognostic value of ROCK2 in OSCC 
cells and its relation with CAF stromal density. In our study, ROCK2 did not stand alone 
as a prognostic marker after multivariate analysis, but was associated with advanced 
clinical stage and increased density of CAF. In practice, ROCK2 may not be an 
independent prognostic factor, but the associations suggest relevance in the tumor 
progression. It has been shown that overexpression of ROCK2 is involved in the 
microRNA-138-mediated enhance of cell stress fiber formation and increased cell 
migration and invasion in oral tongue SCC (Jiang et al., 2010), known to be crucial 
processes to tumor progression and metastasis. Moreover, the association of ROCK2 
tumor expression and CAF abundance may be an indicator of communication within 
the TME and suggests the organization of a more invasion-permissive 
microenvironment, facilitating tumor progression and metastasis. In CAF, expression 
of ROCK2 is predicted to be stimulated by the Rho kinase signaling pathway, which in 
turn may contribute to tumor cell survival, proliferation and progression (Bozóky et al., 
2013). Despite the consistent findings, our study should be interpreted based on its 
limitations. The number of patients and the inclusion of different stages and tumor sites 
in the oral cavity may have influenced the results. Since this is the first report of ROCK2 
as a prognostic marker in OSCC, the validation in an independent cohort of patients 
should be encouraged and would be beneficial to confirm these findings. Unraveling 
some potential biomarkers significantly associated with OSCC progression across 
several studies can, together with clinicopathological evaluation, lead to new target 
opportunities for specific and individualized therapy. 
Furthermore, based on in vitro assays, we observed that CAF-EV 
significantly induce migration and invasion of OSCC cells, which were related to the 
activation of metabolic and structural pathways. Stroma-released EV are able to 
modulate the invasive and metastatic potential of cancer cells, while cancer cells also 
secrete EV to instigate nearby stromal cells in the TME toward a functional transition 
that favors disease progression (Han et al., 2017). Interestingly, CAF-EV were also 
able to induce a disseminated pattern of cell invasion, which is a characteristic of 
aggressiveness and represents the capacity of invasion and metastasis in a tumor. 
This pattern of invasion can be interpreted as the “budding formation” reported before 
in vivo, significantly associated with lymph node metastasis, depth of invasion, and 
CAF-abundant stroma in OSCC (Marangon et al., 2014; Angadi et al., 2015, Seki et 
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al., 2017). To access tumor invasion in a 3D manner, we used an innovative method 
to evaluate cancer cell invasion. The human uterine leiomyoma tissue model was 
developed by the Prof. Tuula Salo’s group (Teppo et al., 2013; Nurmenniemi et al., 
2009), and contains several types of mostly apoptotic cells, soluble and insoluble 
molecules, such as fibroblasts, laminin, and collagens I, III and IV. Therefore, the 
model mimics the normal cancer microenvironment and enhances the reliability of our 
results, since the ECM is closer to reality and less artificial than the previously used 
non-human tissues. 
The protein cargo of CAF-EV has not been evaluated before as done in this 
study. In our study, the differential expressed proteins were mostly related to immune 
processes and defense response, which somehow represents the reactional 
microenvironment of a tumor. Also, CAF-EV treated HSC-3 cells, an aggressive tongue 
SCC cell line, showed activation of pathways related to metabolism and focal 
adhesion. Shan et al (2017) observed that pancreatic CAFs can alter metabolism as 
well as communicate with and respond to cancer cell migration and invasion, and 
concluded that this may be an important mechanism for promoting tumor progression 
in a non-vascular manner in the tumor microenvironment. In the same direction, focal 
adhesion complexes facilitating cell–ECM contact and connection between ECM and 
actin cytoskeleton play mechanistically the key role as they structurally and functionally 
control the cell's morphology and cytoplasmic signaling for survival, proliferation, 
differentiation, and motility (Eke and Cordes, 2015). Our proteomic and mRNA analysis 
did not identify promising targets that could be mechanistically responsible for these 
phenotypes. In fact, this can be acknowledged by the heterogeneity of CAF as 
activated fibroblasts from possibly different sources, but can also be a reflex of the 
diversity of vesicles isolated by differential ultracentrifugation. In both cases, the 
availability of markers or “gold standard” isolation methods to separate these entities 
(source of CAF and vesicle types) are not currently a reality and is a work to be done. 
Despite the exponential growth of the EV research field, it is essential to gain more 
understanding of EV and harness relevant breakthroughs to optimize diagnosis, 
prognosis, and targeting strategies to improve clinical outcome of cancer patients in 
the current era of precision medicine (Han et al., 2017). 
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4 CONCLUSIONS 
 
1. High levels of CAF in the stroma of OSCC are independent prognostic markers and 
could predict shortened time to disease-free survival and an overall decrease in 
survival. In addition, CAF were associated with advanced tumors and not with early 
stage disease, which suggests that CAF density follows OSCC progression. 
 
2. A CAF-rich stroma is associated with advanced disease stage, recurrence, tumor 
grade, depth of invasion, vascular, lymphatic and neural invasion and extra nodal 
metastatic spread, parameters that worsen the prognosis in OSCC. 
 
3. ROCK2 expression in OSCC cells may not be an independent prognostic marker 
but its high expression is associated with advanced disease and CAF abundance, 
which suggests participation on tumor progression.  
 
4. CAF-derived EV can accelerate in vitro invasion and migration of OSCC cell lines 
and these phenotypes may be related to the activation of metabolic and structural 
pathways. 
 
5. CAF-derived EV can stimulate a disseminated pattern of invasion in OSCC cells, 
and this may be related to tumor aggressiveness. 
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